

# CITATION REPORT

List of articles citing

**Psoriasis causes as much disability as other major medical diseases**


**DOI: 10.1016/s0190-9622(99)70112-x**  
**Journal of the American Academy of Dermatology,**  
**1999, 41, 401-7.**

**Source:** <https://exaly.com/paper-pdf/30780263/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1240	Alcohol and psoriasis: a double burden. <b>1999</b> , 135, 1541-2		2
1239	Per-gram cost of medication is by itself a poor indicator for comparing costs of different psoriasis treatments: a retrospective cohort study of the cost of psoriasis treatment with topical corticosteroids versus topical calcipotriene. <b>2000</b> , 4, 121-5		4
1238	Quality of life of psoriasis patients. <b>2000</b> , 14, 241-2		34
1237	Dowling Oration 2000. Dermatology patients: what do they really need?. <b>2000</b> , 25, 444-50		16
1236	Atopic Eczema Prevention Programs  New Therapeutic Concept for Secondary Prevention. <b>2000</b> , 1, 138-147		32
1235	Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?. <i>Journal of the American Academy of Dermatology</i> , <b>2000</b> , 43, 281-5	4.5	174
1234	The burden of psoriasis: a study concerning health-related quality of life among Norwegian adult patients with psoriasis compared with general population norms. <i>Journal of the American Academy of Dermatology</i> , <b>2000</b> , 43, 803-8	4.5	90
1233	Introduction. The magnitude of skin disease in the United States. <b>2000</b> , 18, xv-xxi		27
1232	Physical and psychologic measures are necessary to assess overall psoriasis severity. <i>Journal of the American Academy of Dermatology</i> , <b>2001</b> , 45, 72-6	4.5	134
1231	The contribution of perceptions of stigmatisation to disability in patients with psoriasis. <b>2001</b> , 50, 11-5		203
1230	Skin disorders. <b>2001</b> , 880-883		
1229	Betamethasone Valerate Foam for Treatment of Nonscalp Psoriasis. <b>2001</b> , 5, 303-307		11
1228	Betamethasone valerate foam for treatment of nonscalp psoriasis. <b>2001</b> , 5, 303-7		33
1227	Social coping strategies associated with quality of life decrements among psoriasis patients. <i>British Journal of Dermatology</i> , <b>2001</b> , 145, 610-6	4	60
1226	The impact of psoriasis on quality of life. <i>British Journal of Dermatology</i> , <b>2001</b> , 144 Suppl 58, 33-6	4	80
1225	The impact of psoriasis on quality of life. <i>British Journal of Dermatology</i> , <b>2001</b> , 144, 33-36	4	87
1224	The role of coping strategies in mediating subjective disability in people who have psoriasis. <b>2002</b> , 7, 261-269		26

1223	The bodily suffering of living with severe psoriasis: in-depth interviews with 22 hospitalized patients with psoriasis. <b>2002</b> , 12, 250-61		67
1222	Serum lipids and apolipoproteins in patients with psoriasis. <b>2002</b> , 40, 65-8		56
1221	Trends and developments in the pharmacological treatment of psoriasis. <b>2002</b> , 82, 401-10		6
1220	The suitability of quality-of-life questionnaires for psoriasis research: a systematic literature review. <b>2002</b> , 138, 1221-7; discussion 1227		101
1219	The Development of a Disease-Specific Questionnaire to Assess Quality of Life for Psoriasis Patients: An Analysis of the Reliability, Validity, and Responsiveness of the Psoriasis Quality of Life Questionnaire. <b>2002</b> , 3, 171-179		23
1218	Practical management of psoriasis in the elderly: epidemiology, clinical aspects, quality of life, patient education and treatment options. <b>2002</b> , 19, 847-63		37
1217	Emerging drugs in psoriasis. <b>2002</b> , 7, 69-90		11
1216	Cost-effectiveness comparison of therapy for psoriasis with a methotrexate-based regimen versus a rotation regimen of modified cyclosporine and methotrexate. <i>Journal of the American Academy of Dermatology</i> , <b>2002</b> , 46, 242-50	4.5	21
1215	Efficacy of the 308-nm excimer laser for treatment of psoriasis: results of a multicenter study. <i>Journal of the American Academy of Dermatology</i> , <b>2002</b> , 46, 900-6	4.5	148
1214	Quantifying the harmful effect of psoriasis on health-related quality of life. <i>Journal of the American Academy of Dermatology</i> , <b>2002</b> , 47, 512-8	4.5	207
1213	A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2002</b> , 47, 821-33	4.5	300
1212	Correction. <i>Journal of the American Academy of Dermatology</i> , <b>2002</b> , 46, 250	4.5	
1211	Calidad de vida (II). Calidad de vida en Dermatología. <b>2002</b> , 93, 481-489		14
1210	Quality of life in 6497 Nordic patients with psoriasis. <i>British Journal of Dermatology</i> , <b>2002</b> , 146, 1006-16	4	122
1209	Patients' strategies for coping with psoriasis. <b>2002</b> , 27, 177-84		46
1208	Assessment of depression in subjects with psoriasis vulgaris and lichen planus. <b>2002</b> , 16, 347-52		111
1207	A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis. <b>2002</b> , 41, 269-74		41
1206	Cost of psoriasis: a study on the morbidity and financial effects of having psoriasis in Australia. <b>2002</b> , 43, 255-61		39

1205	Psychological stress, distress and disability in patients with psoriasis: consensus and variation in the contribution of illness perceptions, coping and alexithymia. <b>2002</b> , 41, 157-74		138
1204	Attentional bias for psoriasis-specific and psychosocial threat in patients with psoriasis. <b>2003</b> , 26, 211-24		32
1203	The importance of skin disease as assessed by "willingness-to-pay". <b>2003</b> , 7, 369-71		9
1202	Sensitivity of the Dermatology Life Quality Index to clinical change in patients with psoriasis. <i>British Journal of Dermatology</i> , <b>2003</b> , 149, 318-22	4	58
1201	Development of the PSORIQoL, a psoriasis-specific measure of quality of life designed for use in clinical practice and trials. <i>British Journal of Dermatology</i> , <b>2003</b> , 149, 323-31	4	106
1200	Balneo-phototherapy: a new holistic approach to treating psoriasis. <b>2003</b> , 15, 253-9		1
1199	Self-reported health-related quality of life in persons with HIV infection: results from a multi-site interview project. <b>2003</b> , 1, 12		69
1198	A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. <b>2003</b> , 349, 2004-13		502
1197	Quality of life issues in psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2003</b> , 49, S57-61	4.5	157
1196	Evaluation and management of psoriatic arthritis: the role of biologic therapy. <i>Journal of the American Academy of Dermatology</i> , <b>2003</b> , 49, S125-32	4.5	21
1195	Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice. <i>Journal of the American Academy of Dermatology</i> , <b>2003</b> , 49, 271-5	4.5	114
1194	Effects of alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trial. <b>2003</b> , 4, 131-9		65
1193	Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. <b>2003</b> , 290, 3073-80		300
1192	French people and skin diseases: results of a survey using a representative sample. <b>2003</b> , 139, 1614-9; discussion 1619		69
1191	Suicide Among Former Mineworkers in the Sub Region of Transkei, South Africa: Case Reports. <b>2003</b> , 7, 287-292		3
1190	Etanercept as monotherapy in patients with psoriasis. <b>2003</b> , 349, 2014-22		978
1189	Strategy to manage the treatment of severe psoriasis: considerations of efficacy, safety and cost. <b>2003</b> , 4, 1525-33		43
1188	Adapting the Rheumatoid Arthritis Quality of Life Instrument (RAQoL) for use in Sweden. <b>2003</b> , 32, 320-2; author reply 323-4		2

1187	Case studies in severe psoriasis: A clinical strategy. <b>2003</b> , 14 Suppl 2, 26-46	20
1186	The Importance of Skin Disease as Assessed by Willingness-To-Pay <b>2003</b> , 7, 369-371	15
1185	Measuring adjustment to chronic skin disorders: validation of a self-report measure. <b>2003</b> , 15, 532-49	51
1184	Future Trends in Psychodermatological Psoriasis Research: Somatopsychic or Psychosomatic Focus?. <b>2003</b> , 4, 129-130	4
1183	Evaluation of Psoriasis Symptoms and Disability. 88-103	
1182	The Frequent Use of Oral Retinoids in Combination with other Treatments for Psoriasis: A Retrospective Analysis. <b>2004</b> , 8, 411-414	4
1181	The Effect of Psoriasis on Patients' Quality of Life and Improvements Associated with Alefacept Therapy. <b>2004</b> , 8, 20-25	1
1180	Preface: Psoriasis Today A New Paradigm. <b>2004</b> , 8, 1-2	
1179	Advancements in the treatment of psoriasis: role of biologic agents. <b>2004</b> , 10, 318-25	37
1178	TNFalpha therapy in psoriatic arthritis and psoriasis. <b>2004</b> , 63, 755-8	76
1177	Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis. <b>2004</b> , 63, 162-9	175
1176	Efalizumab for psoriasis?. <b>2004</b> , 13, 551-4	2
1175	Class I topical corticosteroid use by psoriasis patients in an academic practice. <b>2004</b> , 15, 235-8	10
1174	The promise and challenge of new biological treatments for psoriasis: how do they impact quality of life?. <b>2004</b> , 17, 376-82	21
1173	Etanercept for the treatment of psoriasis and psoriatic arthritis. <b>2004</b> , 17, 401-8	24
1172	Psychiatric morbidity in psoriasis: a review. <b>2004</b> , 45, 155-9; quiz 160-1	138
1171	Biological therapies in the systemic management of psoriasis: International Consensus Conference. <i>British Journal of Dermatology</i> , <b>2004</b> , 151 Suppl 69, 3-17	4 139
1170	Detection of psychological distress in patients with psoriasis: low consensus between dermatologist and patient. <i>British Journal of Dermatology</i> , <b>2004</b> , 151, 1227-33	4 98

1169	Successful treatment of psoriasis improves psoriasis-specific but not more general aspects of patients' well-being. <i>British Journal of Dermatology</i> , <b>2004</b> , 151, 1219-26	4	54
1168	Application of Rasch analysis in the development and application of quality of life instruments. <b>2004</b> , 7 Suppl 1, S22-6		281
1167	The burden of psoriasis is not determined by disease severity only. <b>2004</b> , 9, 131-5		94
1166	Divergent beliefs about psoriasis are associated with increased psychological distress. <b>2004</b> , 123, 49-56		41
1165	Targeting cognitive-behaviour therapy to patients' implicit model of psoriasis: results from a patient preference controlled trial. <b>2004</b> , 43, 65-82		76
1164	Psoriasis today--a new paradigm. <b>2004</b> , 8 Suppl, 1-2		
1163	The effect of psoriasis on patients' quality of life and improvements associated with alefacept therapy. <b>2004</b> , 8 Suppl 2, 20-5		9
1162	The frequent use of oral retinoids in combination with other treatments for psoriasis: a retrospective analysis. <b>2004</b> , 8, 411-4		7
1161	Patient satisfaction with psoriasis therapies: an update and introduction to biologic therapy. <b>2004</b> , 8, 310-20		23
1160	Integrating biologic agents into management of moderate-to-severe psoriasis: a consensus of the Canadian Psoriasis Expert Panel. February 27, 2004. <b>2004</b> , 8, 321-37		23
1159	Functional disability and quality of life in patients with ankylosing spondylitis. <b>2004</b> , 24, 57-8; author reply 59-60		5
1158	Quality of life in patients with psoriasis: a systematic literature review. <b>2004</b> , 9, 140-7		271
1157	Quality-of-life issues in psoriasis. <b>2004</b> , 22, 389-95, viii		37
1156	Psoriatic arthritis: prevalence, diagnosis, and review of therapy for the dermatologist. <b>2004</b> , 22, 477-86, x		22
1155	Targeting therapy in psoriatic arthritis. <b>2004</b> , 1, 389-396		1
1154	The burden of illness associated with psoriasis: cost of treatment with systemic therapy and phototherapy in the US. <b>2004</b> , 20, 1929-36		43
1153	Antisense oligonucleotide treatments for psoriasis. <b>2004</b> , 4, 75-81		15
1152	Combination therapy to treat moderate to severe psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2004</b> , 50, 416-30	4.5	142

1151	A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2004</b> , 50, 859-66	4.5	205
1150	Psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2004</b> , 50, 613-22	4.5	16
1149	Measurement of health-related quality of life (HRQOL) associated with skin disease. <i>Journal of the American Academy of Dermatology</i> , <b>2004</b> , 51, S3-4	4.5	8
1148	Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. <i>Journal of the American Academy of Dermatology</i> , <b>2004</b> , 51, 534-42	4.5	464
1147	Determinants of quality of life in patients with psoriasis: a study from the US population. <i>Journal of the American Academy of Dermatology</i> , <b>2004</b> , 51, 704-8	4.5	258
1146	Anti-thyroid thioureylenes in the treatment of psoriasis. <b>2004</b> , 62, 431-7		19
1145	Development and psychometric analysis of the Japanese version of the Nottingham Health Profile: cross-cultural adaptation. <b>2004</b> , 43, 35-41		5
1144	Patient Satisfaction with Psoriasis Therapies: An Update and Introduction to Biologic Therapy. <b>2004</b> , 8, 310-320		26
1143	Integrating Biologic Agents into Management of Moderate-to-Severe Psoriasis: A Consensus of the Canadian Psoriasis Expert Panel. <b>2004</b> , 8, 321-337		38
1142	Safe Psoriasis Control: A New Outcome Measure for the Composite Assessment of the Efficacy and Safety of Psoriasis Treatment. <b>2005</b> , 9, 276-283		1
1141	Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. <b>2005</b> , 141, 31-8		188
1140	Quality of care in patients with psoriasis: an initial clinical study of an international disease management programme. <b>2005</b> , 19, 35-41		41
1139	Recommendations for the topical treatment of psoriasis. <b>2005</b> , 19, 495-9		11
1138	POSTERS. <b>2005</b> , 19, 1-411		1
1137	How patients experience psoriasis: results from a European survey. <b>2005</b> , 19 Suppl 3, 2-6		114
1136	The psoriasis disability index in Chinese patients: contribution of clinical and psychological variables. <b>2005</b> , 44, 925-9		22
1135	Development of the US PSORIQoL: a psoriasis-specific measure of quality of life. <b>2005</b> , 44, 462-9		9
1134	Topical aminolaevulinic acid-based photodynamic therapy as a treatment option for psoriasis? Results of a randomized, observer-blinded study. <i>British Journal of Dermatology</i> , <b>2005</b> , 152, 279-83	4	64

1133	Effect of vitiligo on self-reported health-related quality of life. <i>British Journal of Dermatology</i> , <b>2005</b> , 152, 1165-72	4	145
1132	Current severe psoriasis and the rule of tens. <i>British Journal of Dermatology</i> , <b>2005</b> , 152, 861-7	4	265
1131	Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. <i>British Journal of Dermatology</i> , <b>2005</b> , 152, 954-60	4	107
1130	Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. <i>British Journal of Dermatology</i> , <b>2005</b> , 152, 597-615	4	146
1129	Clinical management decisions are related to the impact of psoriasis on patient-rated quality of life. <i>British Journal of Dermatology</i> , <b>2005</b> , 152, 1256-62	4	29
1128	A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. <i>British Journal of Dermatology</i> , <b>2005</b> , 152, 1304-12	4	586
1127	British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. <i>British Journal of Dermatology</i> , <b>2005</b> , 153, 486-97	4	199
1126	Psoriasis: emerging therapeutic strategies. <b>2005</b> , 4, 19-34		106
1125	The psychometric properties of the psoriasis disability index in United States patients. <b>2005</b> , 125, 665-72		27
1124	[Therapeutic benefits in dermatological therapy. Evaluation of therapy from the physician's and patient's perspective in psoriasis and atopic dermatitis]. <b>2005</b> , 56, 839-42, 844-6		19
1123	[Psychosocial consequences of psoriasis--an empirical study of disease burden in 3753 affected people]. <b>2005</b> , 56, 466-72		26
1122	[Infliximab. Role in the treatment of psoriasis]. <b>2005</b> , 56, 831-2, 834-8		
1121	Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled Phase III trials: part I. <b>2005</b> , 9, 303-12		23
1120	Safe psoriasis control: a new outcome measure for the composite assessment of the efficacy and safety of psoriasis treatment. <b>2005</b> , 9, 276-83		8
1119	Pharmacokinetic-pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis. <b>2005</b> , 22, 1088-100		90
1118	Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139]. <b>2005</b> , 5, 13		44
1117	Psychiatric tests in seborrhoeic dermatitis. <b>2005</b> , 85, 68-9		10
1116	Clinical monograph for drug formulary review: systemic agents for psoriasis/psoriatic arthritis. <b>2005</b> , 11, 33-55		7



1115	Stigmatisation and skin conditions. <b>2005</b> , 44-56	5
1114	Clinical Efficacy of Efalizumab in Patients with Chronic Plaque Psoriasis: Results from Three Randomized Placebo-Controlled Phase III Trials: Part I. <b>2005</b> , 9, 303-312	22
1113	Managing psoriasis as part of a team. <b>2005</b> , 16, 600-603	2
1112	Significance of the stigmatization experience of psoriasis patients: a 1-year follow-up of the illness and its psychosocial consequences in men and women. <b>2005</b> , 85, 27-32	66
1111	Infliximab for inpatient psoriasis management--is there a role?. <b>2005</b> , 16, 314-8	1
1110	The comorbid state of psoriasis patients in a university dermatology practice. <b>2005</b> , 16, 319-23	89
1109	Impact of obesity and smoking on psoriasis presentation and management. <b>2005</b> , 141, 1527-34	307
1108	Is the NHS willing to help clinicians and patients reduce uncertainties about the effects of treatments?. <b>2005</b> , 5, 230-4	6
1107	Treating severe psoriasis: an update. <b>2005</b> , 20, 57-65; quiz 66	1
1106	Psychometric properties of the Dermatology Life Quality Index (DLQI) in 900 Italian patients with psoriasis. <b>2005</b> , 85, 409-13	44
1105	Alefacept in the treatment of psoriasis in patients for whom conventional therapies are inadequate. <b>2005</b> , 211, 256-63	18
1104	Psoriasis treatment: current and emerging directed therapies. <b>2005</b> , 64 Suppl 2, ii87-90; discussion ii91-2	50
1103	Autoimmune Diseases of the Skin. <b>2005</b> ,	4
1102	Emerging drugs for moderate-to-severe psoriasis. <b>2005</b> , 10, 35-52	2
1101	Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. <b>2005</b> , 64, 1150-7	495
1100	Psoriasis assessment tools in clinical trials. <b>2005</b> , 64 Suppl 2, ii65-8; discussion ii69-73	242
1099	Recent Developments in Management of Psoriatic Arthritis. <b>2005</b> , 1, 9-19	8
1098	Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. <b>2005</b> , 141, 1537-41	418

1097	Relationship between smoking and the clinical severity of psoriasis. <b>2005</b> , 141, 1580-4		149
1096	Advances in psoriasis treatment. <b>2005</b> , 366, 1333-5		21
1095	Psychologic factors in psoriasis: consequences, mechanisms, and interventions. <b>2005</b> , 23, 681-94		176
1094	Les critères de suivi du psoriasis. <b>2005</b> , 132, 4-5		
1093	A review of acitretin, a systemic retinoid for the treatment of psoriasis. <b>2005</b> , 6, 1725-34		51
1092	Use of etanercept in the dermatology setting. A review. <b>2005</b> , 6, 49-59		11
1091	The psychosocial burden of psoriasis. <b>2005</b> , 6, 383-92		324
1090	Clobetasol propionate foam in the treatment of psoriasis. <b>2005</b> , 6, 1735-40		13
1089	Adversarial growth in patients undergoing treatment for psoriasis: A prospective study of the ability of patients to construe benefits from negative events. <b>2005</b> , 10, 44-56		20
1088	Diagnosis and treatment of psoriatic arthritis. <i>Journal of the American Academy of Dermatology</i> , <b>2005</b> , 52, 1-19	4.5	80
1087	Medication-related factors affecting health care outcomes and costs for patients with psoriasis in the United States. <i>Journal of the American Academy of Dermatology</i> , <b>2005</b> , 52, 27-31	4.5	14
1086	Decision points for the initiation of systemic treatment for psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2005</b> , 53, 101-7	4.5	56
1085	Involving the patient: impact of inflammatory skin disease and patient-focused care. <i>Journal of the American Academy of Dermatology</i> , <b>2005</b> , 53, S78-85	4.5	36
1084	Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial. <i>Journal of the American Academy of Dermatology</i> , <b>2005</b> , 53, 887-9	4.5	68
1083	Alexithymia in patients with psoriasis: clinical correlates and psychometric properties of the Toronto Alexithymia Scale-20. <b>2005</b> , 58, 89-96		59
1082	The impact of biologics on the quality of life of psoriasis patients and the economics of psoriasis care. <b>2005</b> , 24, 52-7		31
1081	Psoriasis. <b>2005</b> , 352, 1899-912		866
1080	Use of calcipotriene cream (Dovonex cream) following acute treatment of psoriasis vulgaris with the calcipotriene/betamethasone dipropionate two-compound product (Taclonex): a randomized, parallel-group clinical trial. <b>2006</b> , 7, 177-84		30

1079	Cost-effectiveness of moderate-to-severe psoriasis treatment. <b>2006</b> , 7, 157-67		33
1078	Quality of life in patients with psoriasis. <b>2006</b> , 4, 35		173
1077	An Italian study on psoriasis and depression. <b>2006</b> , 212, 123-7		176
1076	The cost-effectiveness and cost of treatment failures associated with systemic psoriasis therapies. <b>2006</b> , 17, 29-37		34
1075	Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective. <i>Journal of the American Academy of Dermatology</i> , <b>2006</b> , 54, 685-704	4.5	127
1074	A European perspective on the challenges of managing psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2006</b> , 54, S81-4	4.5	19
1073	Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial. <i>Journal of the American Academy of Dermatology</i> , <b>2006</b> , 54, S112-9	4.5	38
1072	A randomized, multicenter, double-blind, placebo-controlled phase 2 trial of ISA247 in patients with chronic plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2006</b> , 54, 472-8	4.5	47
1071	Efficacy of etanercept in an integrated multistudy database of patients with psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2006</b> , 54, S101-11	4.5	76
1070	Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. <i>Journal of the American Academy of Dermatology</i> , <b>2006</b> , 55, 598-606	4.5	407
1069	Prevalence and factors associated with use of placebo control groups in randomized controlled trials in psoriasis: a cross-sectional study. <i>Journal of the American Academy of Dermatology</i> , <b>2006</b> , 55, 814-22	4.5	13
1068	Prevalence of cardiovascular risk factors in patients with psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2006</b> , 55, 829-35	4.5	765
1067	Phase II randomized, placebo-controlled trial of M. vaccae-derived protein (PVAC) for the treatment of psoriasis. <b>2006</b> , 24, 5056-63		4
1066	Efalizumab for psoriasis. <b>2006</b> , 1, 503-513		
1065	Joint Damage in Psoriatic Arthritis: Can It be Prevented and is this Important?. <b>2006</b> , 12a, 4-9		1
1064	Biological treatments for psoriasis. <b>2006</b> , 3, 425-436		
1063	Infliximab in the treatment of psoriasis. <b>2006</b> , 1, 515-526		4
1062	Use of etanercept in the treatment of psoriasis and psoriatic arthritis. <b>2006</b> , 1, 259-63		9

1061	Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence. <b>2006</b> , 6, 9		9
1060	Quality of life in psoriasis improves after standardized administration of narrowband UVB phototherapy. <b>2006</b> , 47, 37-40		10
1059	Consistency of data in six phase III clinical studies of a two-compound product containing calcipotriol and betamethasone dipropionate ointment for the treatment of psoriasis. <b>2006</b> , 20, 39-44		33
1058	A 308-nm monochromatic excimer light in the treatment of palmoplantar psoriasis. <b>2006</b> , 20, 523-6		48
1057	Adherence to treatment in patients with psoriasis. <b>2006</b> , 20, 370-9		109
1056	Living with psoriasis. <b>2006</b> , 20, 28-32		10
1055	[Efalizumab—therapy of moderately severe to severe plaque-psoriasis in the dermatologist's practice]. <b>2006</b> , 4 Suppl 1, S3-S12		
1054	Measuring quality of life of patients with different clinical types of psoriasis using the SF-36. <i>British Journal of Dermatology</i> , <b>2006</b> , 154, 844-9	4	77
1053	Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. <i>British Journal of Dermatology</i> , <b>2006</b> , 154, 1161-8	4	92
1052	Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study. <i>British Journal of Dermatology</i> , <b>2006</b> , 155, 160-9	4	42
1051	Update on the use of ciclosporin in immune-mediated dermatoses. <i>British Journal of Dermatology</i> , <b>2006</b> , 155 Suppl 2, 1-16	4	45
1050	European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. <i>British Journal of Dermatology</i> , <b>2006</b> , 155, 729-36	4	196
1049	Developing a quality of life instrument in patients with psoriasis: the Psoriasis Quality of Life Questionnaire (PQLQ). <b>2006</b> , 45, 234-8		13
1048	Impact of psoriasis on quality of life in Kuwait. <b>2006</b> , 45, 418-24		27
1047	The risk of lymphoma in patients with psoriasis. <b>2006</b> , 126, 2194-201		219
1046	Anti-TNF drugs in psoriasis and IBD - Where are we going?. <b>2006</b> , 7, 14-20		
1045	Quality of life of patients with keloid and hypertrophic scarring. <b>2006</b> , 297, 433-8		355
1044	The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients. <b>2006</b> , 298, 309-19		85

1043	[S3-Guidelines for the therapy of psoriasis vulgaris]. <b>2006</b> , 4 Suppl 2, S1-126	58
1042	Current advancements in the treatment of psoriasis: Immunobiologic agents. <b>2006</b> , 6, 99-130	6
1041	Psoriasis and its management. <b>2006</b> , 333, 380-4	73
1040	Biological therapy for psoriasis. <b>2006</b> , 67, 184-7	1
1039	Infliximab for the treatment of psoriasis. <b>2006</b> , 6, 797-805	32
1038	Klassische systemische Therapie der Psoriasis. <b>2006</b> , 32, 190-200	1
1037	Psoriasis vulgaris - Therapie klassisch oder modern?. <b>2006</b> , 82, 153-158	
1036	Psychosoziale Konsequenzen der Psoriasis. <b>2006</b> , 32, 221-225	1
1035	The negative impact of psoriasis on the workplace. <b>2006</b> , 17, 24-8	73
1034	Epidemiology of psoriasis. Review and the German perspective. <b>2006</b> , 212, 327-37	107
1033	Efficacy results of a 52-week, randomised, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet/Dovobet/Taclonex) in the treatment of psoriasis vulgaris. <b>2006</b> , 213, 319-26	62
1032	Efalizumab in the treatment of psoriasis. <b>2006</b> , 10, 57-68	8
1031	Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis. <b>2006</b> , 65, 471-7	65
1030	Risk of myocardial infarction in patients with psoriasis. <b>2006</b> , 296, 1735-41	1208
1029	The epidemiology of psoriasis. <b>2006</b> , 1, 63-75	72
1028	Systemic therapy for moderate-to-severe psoriasis. <b>2006</b> , 1, 77-92	1
1027	Alefacept: clinical use in treating psoriasis. <b>2006</b> , 1, 781-790	
1026	New treatments for psoriasis: which biologic is best?. <b>2006</b> , 17, 96-107	21

1025	Measuring the effects of psoriasis on quality of life. <b>2006</b> , 1, 723-736		1
1024	Do utilization management controls for phototherapy increase the prescription of biologics?. <b>2006</b> , 17, 359-61		12
1023	Adverse events from systemic therapies for psoriasis are common in clinical practice. <b>2006</b> , 17, 288-93		17
1022	Update on the epidemiology and systemic treatment of psoriasis. <b>2007</b> , 3, 171-85		18
1021	Effectiveness of inpatient treatment on quality of life and clinical disease severity in atopic dermatitis and psoriasis vulgaris - a prospective study. <b>2007</b> , 214, 68-76		17
1020	Role of depression in quality of life for patients with psoriasis. <b>2007</b> , 215, 17-27		117
1019	Psoriasis-Arthritis: Aktuelle Datenlage und Bestimmung des Stellenwertes von Ciclosporin. <b>2007</b> , 32, 10-12		
1018	Cost-effectiveness of the two-compound formulation calcipotriol and betamethasone dipropionate compared with commonly used topical treatments in the management of moderately severe plaque psoriasis in Scotland. <b>2007</b> , 23, 1887-901		19
1017	National Psoriasis Foundation clinical consensus on disease severity. <b>2007</b> , 143, 239-42		106
1016	Impairment of sexual life in patients with psoriasis. <b>2007</b> , 214, 144-50		92
1015	Biologic agents in the treatment of psoriasis. <b>2007</b> , 1, 193-217		5
1014	Balancing the benefits and risks of drug treatment: a stated-preference, discrete choice experiment with patients with psoriasis. <b>2007</b> , 143, 1175-9		52
1013	Altered distribution of leukocyte subsets and cytokine production in response to acute psychosocial stress in patients with psoriasis vulgaris. <b>2007</b> , 21, 92-9		65
1012	Psoriasis in the limelight: the remarkable career of an old skin disease. <b>2007</b> , 25, 501-3		2
1011	Quality of life in patients with psoriasis and psoriasis arthritis with a special focus on stigmatization experience. <b>2007</b> , 25, 547-54		59
1010	Pathogenesis and clinical features of psoriasis. <b>2007</b> , 370, 263-271		1221
1009	A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2007</b> , 56, 31.e1-15	4.5	370
1008	Heart disease in psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2007</b> , 57, 347-54	4.5	127

1007	Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey. <i>Journal of the American Academy of Dermatology</i> , <b>2007</b> , 57, 957-62	4.5	102
1006	"Ur skin is the thing that everyone sees and you cant change it!": exploring the appearance-related concerns of young people with psoriasis. <b>2007</b> , 10, 133-41		51
1005	Die Psoriasis-Krankheitskosten korrelieren mit der Schwere des klinischen Befundes und nicht mit der psychischen Krankheitslast. <b>2007</b> , 5, 3-12		0
1004	Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial. <b>2007</b> , 18, 25-31		64
1003	[New therapies in psoriasis]. <b>2007</b> , 129, 377-8		4
1002	A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. <b>2007</b> , 356, 580-92		644
1001	An attempt to formulate an evidence-based strategy in the management of moderate-to-severe psoriasis: a review of the efficacy and safety of biologics and prebiologic options. <b>2007</b> , 8, 617-32		33
1000	Psychological Aspects of Cosmetic Surgery. 182-198		1
999	Efficacy and Safety of Adalimumab Treatment in Patients with Moderate to Severe Psoriasis: A Double-Blind, Randomized Clinical Trial. <b>2007</b> , 13a, 4-11		16
998	Update on infliximab: an intravenous biologic therapy for psoriasis. <b>2007</b> , 2, 707-713		2
997	Etanercept in psoriasis: the evidence of its therapeutic impact. <b>2007</b> , Volume 2, 0-0		
996	Dermatology quality of life instruments: sorting out the quagmire. <b>2007</b> , 127, 2695-6		22
995	Psoriasis: a possible risk factor for development of coronary artery calcification. <i>British Journal of Dermatology</i> , <b>2007</b> , 156, 271-6	4	271
994	Efalizumab in routine use: a clinical experience. <i>British Journal of Dermatology</i> , <b>2007</b> , 156 Suppl 2, 1-6	4	28
993	The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis. <i>British Journal of Dermatology</i> , <b>2007</b> , 156, 945-50	4	76
992	Psoriasis has a major secondary impact on the lives of family members and partners. <i>British Journal of Dermatology</i> , <b>2007</b> , 156, 1245-50	4	106
991	Skin disease is common in rural Nepal: results of a point prevalence study. <i>British Journal of Dermatology</i> , <b>2008</b> , 158, 334-8	4	28
990	Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. <i>British Journal of Dermatology</i> , <b>2008</b> , 158, 549-57	4	115

989	Alcohol consumption and psychological distress in patients with psoriasis. <i>British Journal of Dermatology</i> , <b>2008</b> , 158, 138-40	4	77
988	A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: quality-of-life outcomes of a randomized controlled trial of supervised treatment of psoriasis in a day-care setting. <i>British Journal of Dermatology</i> , <b>2008</b> , 158, 375-81	4	25
987	Assessment of health state utilities of controlled and uncontrolled psoriasis and atopic eczema: a population-based study. <i>British Journal of Dermatology</i> , <b>2008</b> , 158, 351-9	4	60
986	Psychological distress and coping strategies in patients with psoriasis: the PSYCHAE Study. <b>2007</b> , 21, 1161-9		57
985	Costs and quality of life in patients with moderate to severe plaque-type psoriasis in Germany: a multi-center study. <b>2007</b> , 5, 209-18		75
984	Krankheitskosten und Lebensqualität bei Patienten mit mittelschwerer bis schwerer Psoriasis vulgaris in Deutschland: Eine multizentrische Studie. <b>2007</b> , 5, no-no		
983	Treatment goals in psoriasis. <b>2007</b> , 5, 566-74		78
982	Therapieziele bei der Behandlung der Psoriasis. <b>2007</b> , 5, ---		
981	Cost-effectiveness of psoriasis therapy with etanercept in Germany. <b>2007</b> , 5, 762-8		26
980	Kosteneffektivität der Psoriasisbehandlung mit Etanercept in Deutschland. <b>2007</b> , 5, no-no		
979	Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris. <b>2007</b> , 5 Suppl 3, 1-119		75
978	German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version). <b>2007</b> , 299, 111-38		100
977	The relationship between quality of life and skin clearance in moderate-to-severe psoriasis: lessons learnt from clinical trials with infliximab. <b>2008</b> , 300, 537-44		44
976	The psychosocial and occupational impact of chronic skin disease. <b>2008</b> , 21, 54-9		128
975	Low prescription rate for systemic treatments in the management of severe psoriasis vulgaris and psoriatic arthritis in dermatological practices in Berlin and Brandenburg, Germany: results from a patient registry. <b>2008</b> , 22, 1337-42		34
974	Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. <i>British Journal of Dermatology</i> , <b>2008</b> , 159, 274-85	4	109
973	Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. <i>British Journal of Dermatology</i> , <b>2008</b> , 159, 1177-85	4	128
972	Long-term prognosis in patients with psoriasis. <i>British Journal of Dermatology</i> , <b>2008</b> , 159 Suppl 2, 2-9	4	73



971	Long-term data in the treatment of psoriasis. <i>British Journal of Dermatology</i> , <b>2008</b> , 159 Suppl 2, 18-24	4	23
970	The association of dermatologist-diagnosed and self-reported skin diseases with skin-related quality of life in Latino migrant farmworkers. <b>2008</b> , 47, 236-41		14
969	Etanercept provides a more physiological approach in the treatment of psoriasis. <b>2008</b> , 21 Suppl 2, S1-14		8
968	Long-term efficacy of up to 15 months' efalizumab therapy in patients with moderate-to-severe chronic plaque psoriasis. <b>2008</b> , 21 Suppl 3, S6-14		9
967	Sustained clinical response and high infliximab survival in psoriatic arthritis patients: a 3-year long-term study. <b>2008</b> , 37, 293-8		18
966	Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study. <b>2008</b> , 6, 75		34
965	Combined effects of HLA-Cw6, body mass index and waist-hip ratio on psoriasis vulgaris in Chinese Han population. <b>2008</b> , 52, 123-9		35
964	Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. <i>Journal of the American Academy of Dermatology</i> , <b>2008</b> , 58, 106-15	4.5	685
963	Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period. <i>Journal of the American Academy of Dermatology</i> , <b>2008</b> , 58, 125-35	4.5	63
962	Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. <i>Journal of the American Academy of Dermatology</i> , <b>2008</b> , 58, 826-50	4.5	958
961	The impact of psoriasis on health care costs and patient work loss. <i>Journal of the American Academy of Dermatology</i> , <b>2008</b> , 59, 772-80	4.5	115
960	Psoriasis: improving adherence to topical therapy. <i>Journal of the American Academy of Dermatology</i> , <b>2008</b> , 59, 1009-16	4.5	117
959	Economic considerations in psoriasis management. <b>2008</b> , 26, 424-31		26
958	Psoriasis treatment in difficult locations: scalp, nails, and intertriginous areas. <b>2008</b> , 26, 448-59		80
957	Efalizumab in the treatment of psoriasis: mode of action, clinical indications, efficacy, and safety. <b>2008</b> , 26, 509-14		20
956	Options for the treatment of psoriasis: a multifactorial approach. <b>2008</b> , 26, 419-23		7
955	[What are the objectives of moderate to severe psoriasis treatment?]. <b>2008</b> , 135 Suppl 5, S281-4		
954	Adalimumab for the treatment of severe psoriasis and psoriatic arthritis. <b>2008</b> , 8, 363-70		17

953	Psoriasis comorbidities. <b>2008</b> , 19, 5-21	183
952	Poor reporting of quality of life outcomes in dermatology randomized controlled clinical trials. <b>2008</b> , 216, 46-55	28
951	Targeting the interleukin-12/23 cytokine family in the treatment of psoriatic disease. <b>2008</b> , 12 Suppl 1, S1-10	13
950	Treatment of Psoriasis. <b>2008</b> ,	1
949	Moderate-to-Severe Psoriasis. <b>2008</b> ,	
948	[Comparison of patients with psoriasis vulgaris vs. psoriatic arthritis with regard to the reported quality of life]. <b>2008</b> , 47, 343-9	2
947	An updated review of acitretin--a systemic retinoid for the treatment of psoriasis. <b>2008</b> , 4, 953-64	26
946	Psoriasis: characteristics, psychosocial effects and treatment options. <b>2008</b> , 17, 284-90	10
945	TNF.ALPHA. inhibitors treatments for Psoriasis. <b>2008</b> , 28, 27-30	
944	Editorial: Mental Health and Psoriasis. <b>2008</b> , 14a, 8-9	
943	Treatment Satisfaction and Health-related Quality of Life among Individuals with Psoriasis: National Psoriasis Foundation Survey Findings. <b>2008</b> , 14a, 27-34	1
942	Dermatology Trials. <b>2008</b> , 1	
941	Cardiometabolic risk in psoriasis: differential effects of biologic agents. <b>2008</b> , 4, 1229-35	15
940	Infliximab for the treatment of plaque psoriasis. <b>2008</b> , 2, 115-24	18
939	Treatment of severe psoriasis with infliximab. <b>2008</b> , 4, 1165-76	8
938	Moderate and severe plaque psoriasis: cost-of-illness study in Italy. <b>2008</b> , 4, 559-68	54
937	Emerging treatments in the management of psoriasis: biological targeting with ustekinumab. <b>2009</b> , 2, 95-103	
936	Psoriasis--new insights into pathogenesis and treatment. <b>2009</b> , 106, 11-8, quiz 19	36

935	Cost-effectiveness of biologics for moderate-to-severe psoriasis from the perspective of the Swiss healthcare system. <b>2009</b> , 19, 494-9	13
934	Infliximab in the treatment of plaque type psoriasis. <b>2009</b> , 2, 27-37	7
933	Ustekinumab for the treatment of plaque psoriasis. <b>2009</b> , 4, 443-453	1
932	A Canadian self-administered online survey to evaluate the impact of moderate-to-severe psoriasis among patients. <b>2009</b> , 13, 294-302	19
931	Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. <b>2009</b> , 145, 700-3	266
930	National registries of systemic treatment for psoriasis and the European 'Psonet' initiative. <b>2009</b> , 218, 347-56	37
929	Efficacy of efalizumab in psoriasis patients previously treated with tumour necrosis factor blockers. <b>2009</b> , 219, 48-53	3
928	Psoriasis in France and associated risk factors: results of a case-control study based on a large community survey. <b>2009</b> , 218, 103-9	69
927	Severity levels in psoriasis: a separate 'very severe' category not required. <b>2009</b> , 20, 48-51	
926	Identifying the biologic closest to the ideal to treat chronic plaque psoriasis in different clinical scenarios: using a pilot multi-attribute decision model as a decision-support aid. <b>2009</b> , 25, 2835-43	9
925	Fumarsäure bei Psoriasis und endogenem Ekzem. <b>2009</b> , 58, 146-151	
924	Rheumatologists' recommendations on what to do in the dermatology office to evaluate and manage psoriasis patients' joint symptoms. <b>2009</b> , 20, 350-3	13
923	Efficacy and safety of combination Acitretin and Pioglitazone therapy in patients with moderate to severe chronic plaque-type psoriasis: a randomized, double-blind, placebo-controlled clinical trial. <b>2009</b> , 145, 387-93	50
922	Depression and quality of life in psoriasis. <b>2009</b> , 121, 154-61	56
921	The burden of skin disease: quality of life, economic aspects and social issues. <b>2009</b> , 9, 592-4	6
920	Assessing the impact of psoriatic arthritis on patient function and quality of life: lessons learned from other rheumatologic conditions. <b>2009</b> , 38, 320-35	21
919	[15 years of fumaderm: fumaric acid esters for the systemic treatment of moderately severe and severe psoriasis vulgaris]. <b>2009</b> , 7 Suppl 2, S3-16	25
918	Ten years of infliximab: its role in dermatology. <b>2009</b> , 623 Suppl 1, S10-6	1

917	Keloid scarring: bench and bedside. <b>2009</b> , 301, 259-72		152
916	[Treatment of plaque psoriasis with biologics. A meta-analysis of randomized controlled trials]. <b>2009</b> , 104, 125-36		11
915	[Co-morbidities in psoriasis vulgaris]. <b>2009</b> , 60, 116-21		14
914	Efficacy, safety, and cost of Goeckerman therapy compared with biologics in the treatment of moderate to severe psoriasis. <b>2009</b> , 48, 653-8		17
913	Psoriasis: an opportunity to identify cardiovascular risk. <i>British Journal of Dermatology</i> , <b>2009</b> , 160, 1-7	4	46
912	Quality of life and psychological distress in patients with cutaneous lymphoma. <i>British Journal of Dermatology</i> , <b>2009</b> , 160, 815-22	4	68
911	More than skin deep: atherosclerosis as a systemic manifestation of psoriasis. <i>British Journal of Dermatology</i> , <b>2009</b> , 161, 1-7	4	99
910	Adalimumab treatment for severe recalcitrant chronic plaque psoriasis. <b>2009</b> , 34, 784-8		26
909	From basic research to biological treatments: psoriasis publications over the past 15 years. <b>2009</b> , 34, e91-3		6
908	Ustekinumab. <b>2009</b> , 8, 355-6		18
907	Combined effects of HLA-Cw6 and cigarette smoking in psoriasis vulgaris: a hospital-based case-control study in China. <b>2009</b> , 23, 132-7		46
906	A critical appraisal of evidence-based guidelines for the treatment of psoriasis vulgaris: 'AGREE-ing' on a common base for European evidence-based psoriasis treatment guidelines. <b>2009</b> , 23, 782-7		26
905	Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis. <b>2009</b> , 23, 896-904		87
904	Moderate to severe psoriasis: from topical to biological treatment. <b>2009</b> , 23, 1324-6		13
903	Quality of life in patients with scalp psoriasis treated with calcipotriol/betamethasone dipropionate scalp formulation: a randomized controlled trial. <b>2009</b> , 23, 919-26		30
902	Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study. <b>2009</b> , 23, 1374-82		67
901	Approach to managing patients with nail psoriasis. <b>2009</b> , 23 Suppl 1, 15-21		92
900	European S3-guidelines on the systemic treatment of psoriasis vulgaris. <b>2009</b> , 23 Suppl 2, 1-70		586

899	Psoriasis is independently associated with psychiatric morbidity and adverse cardiovascular risk factors, but not with cardiovascular events in a population-based sample. <b>2010</b> , 24, 885-92		82
898	Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis. <b>2009</b> , 219, 239-49		36
897	Documento de consenso sobre la evaluación y el tratamiento de la psoriasis moderada/grave del Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología. <b>2009</b> , 100, 277-286		80
896	Directrices españolas basadas en la evidencia para el tratamiento de la psoriasis moderada a grave con agentes biológicos. <b>2009</b> , 100, 386-413		61
895	Persistent hypoglycemia in a patient with diabetes taking etanercept for the treatment of psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2009</b> , 60, 1032-6	4-5	12
894	[Biologic therapies in the treatment of psoriasis]. <b>2009</b> , 38, 832-43		1
893	Consensus Document on the Evaluation and Treatment of Moderate to Severe Psoriasis. Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology. <b>2009</b> , 100, 277-288		1
892	Spanish Evidence-Based Guidelines on the Treatment of Moderate to Severe Psoriasis with Biologic Agents. <b>2009</b> , 100, 386-413		1
891	Ustekinumab: a new option in psoriasis therapy. <b>2009</b> , 69, 1141-52		29
890	The impact of itch symptoms in psoriasis: results from physician interviews and patient focus groups. <b>2009</b> , 7, 62		95
889	Comorbidities in dermatology. <b>2009</b> , 27, 137-47, vi		23
888	Efficacy of a single educative intervention in patients with chronic plaque psoriasis. <b>2009</b> , 219, 316-21		28
887	Burden of skin diseases. <b>2009</b> , 9, 271-83		57
886	Impact of psoriasis on patients' work and productivity: a retrospective, matched case-control analysis. <b>2009</b> , 10, 407-10		32
885	Economic burden of psoriasis compared to the general population and stratified by disease severity. <b>2009</b> , 25, 2429-38		78
884	Diminished neural and cognitive responses to facial expressions of disgust in patients with psoriasis: a functional magnetic resonance imaging study. <b>2009</b> , 129, 2613-9		32
883	Tratamiento tópico o sistémico en la psoriasis. ¿Dilema o acuerdo?. <b>2009</b> , 24, 227-229		
882	Evaluation and management of psoriasis: an internist's guide. <b>2009</b> , 93, 1291-303		39

881	Differential diagnosis of psoriasis. <b>2009</b> , 83, 24-5		8
880	You're the flight surgeon. Gravity induced loss of consciousness and psoriasis. <b>2009</b> , 80, 501-2		0
879	Approche psychologique des dermatoses. <b>2010</b> , 5, 1-5		
878	The Psychological Impact of Psoriasis. <b>2010</b> , 2, 163-167		2
877	Psoriasis y s̄ndrome metab̄lico. <b>2010</b> , 25, 133-145		7
876	Differing effect of systemic anti psoriasis therapies on platelet physiology--a case report and review of literature. <b>2010</b> , 10, 2		5
875	Psoriasis: depression, anxiety, smoking, and drinking habits. <b>2010</b> , 23, 174-80		113
874	The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics. <b>2010</b> , 24, 548-54		103
873	Evidence-based recommendations to assess psoriasis severity: systematic literature review and expert opinion of a panel of dermatologists. <b>2010</b> , 24 Suppl 2, 2-9		44
872	Exploring the association between cardiovascular and other disease-related risk factors in the psoriasis population: the need for increased understanding across the medical community. <b>2010</b> , 24, 1371-7		31
871	Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents. <b>2010</b> , 160, 810-20		97
870	Community-based epidemiological study of psychosocial effects of acne in Japanese adolescents. <b>2010</b> , 37, 617-22		38
869	A calcipotriene/betamethasone dipropionate two-compound scalp formulation in the treatment of scalp psoriasis in Hispanic/Latino and Black/African American patients: results of the randomized, 8-week, double-blind phase of a clinical trial. <b>2010</b> , 49, 1328-33		32
868	Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial. <i>British Journal of Dermatology</i> , <b>2010</b> , 162, 137-46	4	76
867	The economic impact of high-need psoriasis in daily clinical practice before and after the introduction of biologics. <i>British Journal of Dermatology</i> , <b>2010</b> , 162, 1324-9	4	38
866	Updates from the British Association of Dermatologists 89th Annual Meeting, 7-10 July 2009, Glasgow, U.K. <i>British Journal of Dermatology</i> , <b>2010</b> , 163, 27-37	4	2
865	Clinical and genetic predictors of response to narrowband ultraviolet B for the treatment of chronic plaque psoriasis. <i>British Journal of Dermatology</i> , <b>2010</b> , 163, 1056-63	4	25
864	Update of the management of chronic psoriasis: new approaches and emerging treatment options. <b>2010</b> , 3, 25-37		4

863	Social Networking and the Psoriasis Patient. <b>2010</b> , 16a, 43-48	
862	Adalimumab Treatment and Work Productivity in Patients with Moderate to Severe Psoriasis: Results from a Prospective Clinical Trial. <b>2010</b> , 16a, 2-6	
861	Ustekinumab and Marked Clinical Responses in Patients with Moderate to Severe Psoriasis. <b>2010</b> , 16a, 3-11	
860	Guidelines on the Management of Psoriasis in South Africa. <b>2010</b> , 100, 255	11
859	Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasis. <b>2010</b> , 5, 11-22	8
858	Association between Psoriasis and Cardiovascular Risk Factors in Korean Patients. <b>2010</b> , 22, 300-6	37
857	Impact of Psoriasis on Quality of Life: Relationship between Clinical Response to Therapy and Change in Health-related Quality of Life. <b>2010</b> , 22, 389-96	36
856	Updated Turkish Guidelines for the Management of Psoriasis with Biologic Agents. <b>2010</b> , 44, 105-112	6
855	How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review. <b>2010</b> , 130, 933-43	152
854	The values of treatments for chronic inflammatory skin diseases; challenges of the market of health. <b>2010</b> , 21, 1-2	2
853	Psychological and Social Implications of Aging Skin: Normal Aging and the Effects of Cutaneous Disease. <b>2010</b> , 949-957	9
852	The use of ustekinumab in autoimmune disease. <b>2010</b> , 10, 587-604	37
851	Epidemiology of moderate-to-severe plaque psoriasis in a Canadian surveyed population. <b>2010</b> , 14, 167-74	14
850	Prior authorization for topical psoriasis treatments: is it cost-beneficial for managed care?. <b>2010</b> , 21, 178-84	7
849	Recent trends in systemic psoriasis treatment costs. <b>2010</b> , 146, 46-54	60
848	Psoriasis: impact and management of moderate to severe disease. <b>2010</b> , 19, 10-7	5
847	Psoriasis: characteristics, psychosocial effects and treatment options. <b>2010</b> , 19, 820, 822-5	2
846	Managing Parkinson's disease during surgery. <b>2010</b> , 341, c5718	46

845	Psoriasis and its treatment with adalimumab. <b>2010</b> , 10, 133-52		4
844	[A new view of psoriasis]. <b>2010</b> , 137, 3-7		
843	Psoriasis. <b>2010</b> , 1-60		24
842	Adverse Reactions During Biological Therapy for Psoriasis: Results of a Survey of the Spanish Psoriasis Group. <b>2010</b> , 101, 156-163		
841	Factors affecting sleep quality in patients with psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2010</b> , 63, 114-23	4-5	77
840	The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial. <i>Journal of the American Academy of Dermatology</i> , <b>2010</b> , 62, 812-8	4-5	121
839	Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial. <i>Journal of the American Academy of Dermatology</i> , <b>2010</b> , 63, 457-65	4-5	139
838	Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: comparison of adverse event-free response days in the CHAMPION trial. <i>Journal of the American Academy of Dermatology</i> , <b>2010</b> , 63, 1011-8	4-5	26
837	The use of cyclosporine in dermatology: part II. <i>Journal of the American Academy of Dermatology</i> , <b>2010</b> , 63, 949-72; quiz 973-4	4-5	72
836	[Comorbidities in psoriasis]. <b>2010</b> , 101 Suppl 1, 55-61		2
835	Assessing long-term drug safety: lessons (re) learned from raptiva. <b>2010</b> , 29, 16-9		33
834	Comorbidities in psoriasis patients. <b>2010</b> , 29, 10-5		83
833	Can early treatment with biologics modify the natural history of comorbidities?. <b>2010</b> , 23, 181-93		17
832	Efectos adversos observados durante la terapia biológica en la psoriasis. Resultados de una encuesta al Grupo Español de Psoriasis. <b>2010</b> , 101, 156-163		10
831	Topical treatment of psoriasis. <b>2010</b> , 11, 1999-2009		41
830	Molecular dissection of psoriasis: integrating genetics and biology. <b>2010</b> , 130, 1213-26		206
829	Biologic therapies for psoriasis: do we use them enough?. <b>2010</b> , 5, 497-499		1
828	Diagnosis and management of psoriasis and psoriatic arthritis in adults: summary of SIGN guidance. <b>2010</b> , 341, c5623		33



827	The latest advances in pharmacogenetics and pharmacogenomics in the treatment of psoriasis. <b>2010</b> , 14, 81-93		28
826	Efficacy and safety of ustekinumab and etanercept for the treatment of psoriasis. <b>2010</b> , 10, 1105-12		5
825	Cost effectiveness of the two-compound formulation calcipotriol and betamethasone dipropionate gel in the treatment of scalp psoriasis in Scotland. <b>2011</b> , 27, 269-84		16
824	A psoriasis-specific model to support decision making in practice - UK experience. <b>2011</b> , 27, 205-23		14
823	Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial. <b>2011</b> , 12, 51-62		35
822	Quality of life in patients with immune-mediated inflammatory diseases. <b>2011</b> , 88, 7-19		9
821	Physician and Patient Perception of Disease Severity, Quality of Life, and Treatment Satisfaction in Psoriasis: An Observational Study in Spain. <b>2011</b> , 102, 270-276		
820	Autoimmune Diseases of the Skin. <b>2011</b> ,		4
819	Effects of adalimumab versus placebo on risk of symptom worsening in psoriasis and subsequent impacts on health-related quality-of-life: analysis of pooled data from two randomized, double-blind, placebo-controlled, multicentre clinical trials. <b>2011</b> , 31, 51-60		7
818	New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab. <b>2011</b> , 12, 113-25		49
817	[Physician and patient perception of disease severity, quality of life, and treatment satisfaction in psoriasis: an observational study in Spain]. <b>2011</b> , 102, 270-6		10
816	Epidemiology and quality of life of patients with psoriasis in Chile. <b>2011</b> , 102, 810-6		21
815	Increased risk of acute myocardial infarction in patients with psoriasis: a 5-year population-based study in Taiwan. <i>Journal of the American Academy of Dermatology</i> , <b>2011</b> , 64, 495-501	4.5	61
814	Quality of life in cutaneous lupus erythematosus. <i>Journal of the American Academy of Dermatology</i> , <b>2011</b> , 64, 849-58	4.5	103
813	Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study. <i>Journal of the American Academy of Dermatology</i> , <b>2011</b> , 64, 671-81	4.5	64
812	Psoriasis in the elderly: from the Medical Board of the National Psoriasis Foundation. <i>Journal of the American Academy of Dermatology</i> , <b>2011</b> , 65, 537-545	4.5	53
811	Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. <i>Journal of the American Academy of Dermatology</i> , <b>2011</b> , 65, 137-74	4.5	343
810	Epidemiology and Quality of Life of Patients With Psoriasis in Chile. <b>2011</b> , 102, 810-816		1

809	Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. <i>British Journal of Dermatology</i> , <b>2011</b> , 165, 661-8	4	109
808	A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency. <b>2011</b> , 12, 2041-54		49
807	Dermatologist Patient In-Office Discussions of Psoriasis: Focus on Quality of Life. <b>2011</b> , 17a, 290-297		
806	A Strategic Approach to Setting the Research Agenda in Psoriasis. <b>2011</b> , 17a, 97-102		3
805	Evaluating Psoriasis: A Review of the Assessments Most Commonly Used in Clinical Trials. <b>2011</b> , 17a, 259-266		0
804	IMMUNOMODULATORS AND THE BIOLOGICS IN CUTANEOUS EMERGENCIES. 34-49		
803	Understanding and treating your residents' psoriasis. <b>2011</b> , 13, 12-18		
802	Psoriasis Patient Physician Interactions. <b>2011</b> , 17a, 298-302		
801	A 41 year old man with an itchy rash. <b>2011</b> , 343, d7320		
800	Exploring adherence issues in psoriasis care. <b>2011</b> , 22, 549-553		
799	Care of Generalized Psoriasis in Elderly Patients beyond Topical Therapy: A Review and a Proposed Algorithm. <b>2011</b> , 17a, 105-116		
798	Psoriasis Treatments: A Review of the Current Research Pipeline. <b>2011</b> , 17a, 11-23		2
797	Use of pharmacogenomics in psoriasis. <b>2011</b> , 1, 399-411		4
796	Combined treatment with etanercept 50 mg once weekly and narrow-band ultraviolet B phototherapy in chronic plaque psoriasis. <b>2011</b> , 21, 568-72		28
795	Stress and quality of life in psoriasis: an update. <b>2011</b> , 50, 783-92		52
794	Alcohol, psoriasis, liver disease, and anti-psoriasis drugs. <b>2011</b> , 50, 1323-31		27
793	Low-dose, short-term ciclosporin (Neoral ) therapy is effective in improving patients' quality of life as assessed by Skindex-16 and GHQ-28 in mild to severe psoriasis patients. <b>2011</b> , 38, 465-72		15
792	Indicators of health quality in 154 Turkish patients with psoriasis. <b>2011</b> , 38, 600-3		2

791	A prospective case-controlled cohort study of endothelial function in patients with moderate to severe psoriasis. <i>British Journal of Dermatology</i> , <b>2011</b> , 164, 26-32	4	25
790	Erectile dysfunction in patients with psoriasis: increased prevalence, an unmet need, and a chance to intervene. <i>British Journal of Dermatology</i> , <b>2011</b> , 164, 103-9	4	38
789	Sun exposure induces rapid immunological changes in skin and peripheral blood in patients with psoriasis. <i>British Journal of Dermatology</i> , <b>2011</b> , 164, 344-55	4	42
788	A systematic investigation of confirmed autoimmune loci in early-onset psoriasis reveals an association with IL2/IL21. <i>British Journal of Dermatology</i> , <b>2011</b> , 164, 660-4	4	20
787	Quality of life and sexual health in patients with genital psoriasis. <i>British Journal of Dermatology</i> , <b>2011</b> , 164, 1247-55	4	81
786	Patient-reported outcomes in psoriasis research and practice. <i>British Journal of Dermatology</i> , <b>2011</b> , 165, 1361-2	4	8
785	Medical comorbidity associated with psoriasis in adults: a population-based study. <i>British Journal of Dermatology</i> , <b>2011</b> , 165, 1037-43	4	113
784	Porphyria cutanea tarda and glucose metabolism alterations. <i>British Journal of Dermatology</i> , <b>2011</b> , 165, 1362-3; author reply 1363-4	4	1
783	Atherosclerosis as a systemic feature of psoriasis. <b>2011</b> , 36, 451-2		4
782	Economic burden of comorbidities in patients with psoriasis is substantial. <b>2011</b> , 25, 157-63		83
781	Impact of Avène hydrotherapy on the quality of life of atopic and psoriatic patients. <b>2011</b> , 25 Suppl 1, 24-9		21
780	Psoriasis: is it the tip of the iceberg for the quality of life of patients and their families?. <b>2011</b> , 25, 1282-7		29
779	Maximizing patient adherence for optimal outcomes in psoriasis. <b>2011</b> , 25 Suppl 4, 9-14		89
778	S3 Guidelines on the treatment of psoriasis vulgaris Update 2011. <b>2011</b> , 9, S1-S95		58
777	[S3-guidelines for the treatment of psoriasis vulgaris Update 2011]. <b>2011</b> , 9 Suppl 2, S1-104		21
776	Traitement du psoriasis en pratique pour le rhumatologue. <b>2011</b> , 78, 145-151		0
775	Large-scale, prospective, observational studies in patients with psoriasis and psoriatic arthritis: A systematic and critical review. <b>2011</b> , 11, 32		42
774	Long-term prognosis and comorbidities associated with psoriasis in the Newfoundland and Labrador founder population. <b>2011</b> , 15, 37-47		21

773	Health-related quality of life in patients with psoriasis. <b>2011</b> , 15, 29-36	17
772	Psoriasis verursacht hohe Kosten, mindert die Produktivität am Arbeitsplatz und verringert die Lebensqualität. <b>2011</b> , 37, 353-359	5
771	Zeitmanagement und Lebensqualität nach Umstellung einer topischen und/oder Fototherapie auf Fumarsäureester bei Patienten mit Psoriasis. <b>2011</b> , 37, 249-253	
770	Chronic diseases influence major life changing decisions: a new domain in quality of life research. <b>2011</b> , 104, 241-50	21
769	The Turkish Version of the Psoriasis Disability Index: A Validation and Reliability Study. <b>2011</b> , 45, 24-28	1
768	Adherence in the treatment of psoriasis: a systematic review. <b>2011</b> , 222, 363-74	125
767	Summary of the International Federation of Psoriasis Associations (IFPA) meeting: a report from the GRAPPA 2009 annual meeting. <b>2011</b> , 38, 530-9	1
766	Management of psoriatic arthritis from the view of the dermatologist. <b>2011</b> , 7, 588-98	41
765	Psoriasis y nuevas terapias. <b>2011</b> , 22, 767-772	
764	Patient preferences for psoriasis treatments: process characteristics can outweigh outcome attributes. <b>2011</b> , 147, 1285-94	73
763	Patient education in chronic skin diseases: a systematic review. <b>2011</b> , 91, 12-7	49
762	Ustekinumab for the treatment of psoriasis. <b>2011</b> , 7, 155-64	8
761	Therapeutic efficacy and safety of propylthiouracil in psoriasis: an open-label study. <b>2011</b> , 77, 673-6	6
760	Self-management in daily life with psoriasis: an integrative review of patient needs for structured education. <b>2012</b> , 2012, 890860	8
759	Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting. <b>2012</b> , 148, 487-94	71
758	Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment. <b>2012</b> , 71, 1143-50	112
757	The direct healthcare insurer and out-of-pocket expenditures of psoriasis: evidence from a United States national survey. <b>2012</b> , 23, 240-54	17
756	Psoriasis: symptoms, treatments and its impact on quality of life. <b>2012</b> , 17, 524, 526, 528	12

755	Physical and mental impact of psoriasis severity as measured by the compact Short Form-12 Health Survey (SF-12) quality of life tool. <b>2012</b> , 132, 1111-6	40
754	Challenges for synthesising data in a network of registries for systemic psoriasis therapies. <b>2012</b> , 224, 236-43	37
753	Antipsoriatic drug development: challenges and new emerging therapies. <b>2012</b> , 6, 3-21	8
752	Beyond skin: the need for a new approach to the management of psoriasis in primary care. <b>2012</b> , 62, 568-9	13
751	A review of the use of the dermatology life quality index as a criterion in clinical guidelines and health technology assessments in psoriasis and chronic hand eczema. <b>2012</b> , 30, 237-44, viii	13
750	Overview of health status quality-of-life measures. <b>2012</b> , 30, 209-21, xiii	10
749	Clinical and Therapeutic Evaluation of Patients with Moderate to Severe Psoriasis in Spain: The Secuence Study. <b>2012</b> , 103, 897-904	12
748	Perspective: Don't be superficial. <b>2012</b> , 492, S55	5
747	Space-based estimation of the solar UV-B doses for psoriasis heliotherapy in Poland using OMI data for the period 2005-2011. <b>2012</b> , 117, 240-6	10
746	Health-related quality-of-life assessment in dermatologic practice: relevance and application. <b>2012</b> , 30, 323-32, x	19
745	Investigational VEGF antagonists for psoriasis. <b>2012</b> , 21, 33-43	27
744	Quality-of-life instruments: evaluation of the impact of psoriasis on patients. <b>2012</b> , 30, 281-91, ix	29
743	[Integrated approach to comorbidity in patients with psoriasis.Working Group on Psoriasis-associated Comorbidities]. <b>2012</b> , 103 Suppl 1, 1-64	25
742	Increased risk of psoriasis following obstructive sleep apnea: a longitudinal population-based study. <b>2012</b> , 13, 285-9	51
741	[Multiplatform application to determine presence of metabolic syndrome and cardiovascular risk in patients with psoriasis]. <b>2012</b> , 103, 111-9	2
740	Cost-effectiveness analysis of a patient-centered care model for management of psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2012</b> , 66, 563-70	4.5 36
739	Teaching empathy to undergraduate medical students using a temporary tattoo simulating psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2012</b> , 67, 93-9	4.5 8
738	Quality of life in patients with bullous dermatoses. <b>2012</b> , 30, 103-7	27

737	Ethical considerations in health care reform: pros and cons of the Affordable Care Act. <b>2012</b> , 30, 151-5	2
736	Perspectives of psoriasis patients in Turkey. <b>2012</b> , 30, 7-10	4
735	Budget impact analysis of ustekinumab in the management of moderate to severe psoriasis in Greece. <b>2012</b> , 12, 10	3
734	Evaluation of the impact of writing exercises interventions on quality of life in patients with psoriasis undergoing systemic treatments. <i>British Journal of Dermatology</i> , <b>2012</b> , 167, 1254-64	4 10
733	Economic burden of moderate to severe plaque psoriasis in Canada. <b>2012</b> , 51, 1432-40	34
732	Specialized dermatological care for marginalized populations and education at the primary care level: is community dermatology a feasible proposal?. <b>2012</b> , 51, 1345-50	12
731	Current and emerging systemic treatment strategies for psoriasis. <b>2012</b> , 72, 1867-80	26
730	Integrated Approach to Comorbidity in Patients With Psoriasis. <b>2012</b> , 103, 1-64	5
729	Multiplatform Application to Determine Presence of Metabolic Syndrome and Cardiovascular Risk in Patients With Psoriasis. <b>2012</b> , 103, 111-119	
728	Clinical and therapeutic evaluation of patients with moderate to severe psoriasis in Spain: the secence study. <b>2012</b> , 103, 897-904	
727	Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis. <b>2012</b> , 29, 620-34	51
726	Dyadic adjustment, family coping, body image, quality of life and psychological morbidity in patients with psoriasis and their partners. <b>2012</b> , 19, 260-9	19
725	The burden of moderate to severe psoriasis: an overview. <b>2012</b> , 30, 1005-13	49
724	Melasma quality of life measures. <b>2012</b> , 30, 269-80, viii	27
723	Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy. <b>2012</b> , 7, e33486	80
722	Patient considerations in the management of mental stress in psoriasis. <b>2012</b> , 41	0
721	Psoriasis: Epidemiology, Clinical and Histological Features, Triggering Factors, Assessment of Severity and Psychosocial Aspects. <b>2012</b> ,	3
720	Quality of life issues and measurement in patients with psoriasis. <i>Psoriasis: Targets and Therapy</i> , <b>2012</b> , 13	2.4 0

719	Psoriasis: epidemiology, natural history, and differential diagnosis. <i>Psoriasis: Targets and Therapy</i> , <b>2012</b> , 67	2.4	4
718	[A decade of biologics in dermatology]. <b>2012</b> , 63 Suppl 1, 53-8		
717	Application of the dermatology life quality index in clinical trials of biologics for psoriasis. <b>2012</b> , 18, 179-85		11
716	Psoriasis following bariatric surgery: clinical evolution and impact on quality of life on 10 patients. <b>2012</b> , 22, 877-80		51
715	Jeuk bij psoriasis en wat daaraan te doen valt. <b>2012</b> , 28, 33-40		
714	Psoriasis in patients older than 65 years. A comparative study with younger adult psoriatic patients. <b>2012</b> , 16, 586-91		16
713	Assessing quality of life in patients with psoriasis and its improvement with treatment. <b>2012</b> , 26, 661-2		1
712	Psodisk, a new visual method for assessing the burden of psoriasis on patients. <b>2012</b> , 26, 1163-6		19
711	Current psoriasis treatments in an Italian population and their association with socio-demographical and clinical features. <b>2012</b> , 26, 976-82		13
710	Efficacy of systemic therapies for moderate-to-severe psoriasis: a systematic review and meta-analysis of long-term treatment. <b>2012</b> , 26, 1331-44		48
709	Analysis of three outcome measures in moderate to severe psoriasis: a registry-based study of 2450 patients. <i>British Journal of Dermatology</i> , <b>2012</b> , 166, 797-802	4	49
708	Tomesa balneophototherapy in mild to severe psoriasis: a retrospective clinical trial in 174 patients. <b>2012</b> , 28, 169-71		3
707	S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update. <b>2012</b> , 10 Suppl 2, S1-95		197
706	Isolation and structural elucidation of abietic acid as the main adulterant in an herbal drug for the treatment of psoriasis. <b>2012</b> , 66, 345-8		9
705	Dramatic impact of a Psoriasis Area and Severity Index 90 response on the quality of life in patients with psoriasis: an analysis of Japanese clinical trials of infliximab. <b>2012</b> , 39, 253-9		55
704	Impact of ustekinumab on health-related quality of life in Japanese patients with moderate-to-severe plaque psoriasis: results from a randomized, double-blind, placebo-controlled phase 2 / 3 trial. <b>2012</b> , 39, 761-9		18
703	The psych and inflammatory skin disease. <i>British Journal of Dermatology</i> , <b>2012</b> , 166, 911	4	3
702	Significant delay in the introduction of systemic treatment of moderate to severe psoriasis: a prospective multicentre observational study in outpatients from hospital dermatology departments in France. <i>British Journal of Dermatology</i> , <b>2012</b> , 167, 643-8	4	24

701	Updates from the British Association of Dermatologists 91st annual meeting, 5-7 July 2011, London, U.K. <i>British Journal of Dermatology</i> , <b>2012</b> , 167, 232-9	4	1
700	Guidance on the diagnosis and clinical management of psoriasis. <b>2012</b> , 37 Suppl 1, 13-8		24
699	A framework for improving the quality of care for people with psoriasis. <b>2012</b> , 26 Suppl 4, 1-16		27
698	Does p40-targeted therapy represent a significant evolution in the management of plaque psoriasis?. <b>2012</b> , 26 Suppl 5, 2-8		5
697	Health-related quality of life of pediatric patients with moderate to severe plaque psoriasis: comparisons to four common chronic diseases. <b>2012</b> , 171, 485-92		48
696	Psoriasis increased the risk of diabetes: a meta-analysis. <b>2012</b> , 304, 119-25		35
695	German S3-guidelines on the treatment of psoriasis vulgaris (short version). <b>2012</b> , 304, 87-113		83
694	Use of digital infrared imaging in the assessment of childhood psoriasis. <b>2013</b> , 19, e549-51		5
693	Psoriasis and psycho-dermatology. <b>2013</b> , 3, 117-30		28
692	Barriers to the prescription of systemic therapies for moderate-to-severe psoriasis--a multinational cross-sectional study. <b>2013</b> , 305, 899-907		37
691	Presentation of psoriatic arthritis in the literature: a twenty-year bibliometric evaluation. <b>2013</b> , 33, 361-7		12
690	Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents. <b>2013</b> , 27, 359-73		25
689	UVA-1 laser in the treatment of palmoplantar pustular psoriasis. <b>2013</b> , 31, 434-8		21
688	Demographic characteristics and health-related quality of life of patients with moderate-to-severe psoriasis: The VACAP study. <b>2013</b> , 104, 807-814		
687	Health-related quality of life in psoriasis: important role of personal resources. <b>2013</b> , 93, 551-6		28
686	Treatment and referral patterns for psoriasis in United Kingdom primary care: a retrospective cohort study. <b>2013</b> , 13, 9		18
685	Adalimumab in the treatment of plaque-type psoriasis and psoriatic arthritis. <b>2013</b> , 13, 1325-34		8
684	Adherence to medication in patients with psoriasis: a systematic literature review. <i>British Journal of Dermatology</i> , <b>2013</b> , 168, 20-31	4	109



683	Directrices españolas basadas en la evidencia para el tratamiento de la psoriasis con agentes biológicos, 2013. I. Consideraciones de eficacia y selección del tratamiento. <b>2013</b> , 104, 694-709		83
682	Spanish evidence-based guidelines on the treatment of psoriasis with biologic agents, 2013. Part 1: on efficacy and choice of treatment. Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology. <b>2013</b> , 104, 694-709		17
681	Patients' educational needs about topical treatments for psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2013</b> , 68, e163-8	4-5	10
680	Tratamiento de la psoriasis moderada-grave. Dónde estamos, dónde estamos y adónde vamos. <b>2013</b> , 28, 257-259		
679	Expression of soluble sCD163 in serum of psoriatic patients is modulated by Goeckerman therapy. <b>2013</b> , 41, 158-62		
678	Item-level psychometric properties for a new patient-reported psoriasis symptom diary. <b>2013</b> , 16, 1014-22		21
677	Topical therapies for the treatment of plaque psoriasis: systematic review and network meta-analyses. <i>British Journal of Dermatology</i> , <b>2013</b> , 168, 954-67	4	55
676	Demographic characteristics and health-related quality of life of patients with moderate-to-severe psoriasis: The VACAP study. <b>2013</b> , 104, 807-14		14
675	Psychiatric morbidity in pemphigus and psoriasis: a comparative study from India. <b>2013</b> , 6, 151-6		29
674	Sulphurous medicinal waters increase somatostatin release: It is a possible mechanism of anti-inflammatory effect of balneotherapy in psoriasis. <b>2013</b> , 5, 109-118		10
673	A prospective, interventional assessment of psoriasis quality of life using a nonskin-specific validated instrument that allows comparison with other major medical conditions. <i>Journal of the American Academy of Dermatology</i> , <b>2013</b> , 69, e79-88	4-5	26
672	Quality of life and cost of illness in patients with psoriasis in Malaysia: a multicenter study. <b>2013</b> , 52, 314-22		19
671	Effect of store and forward teledermatology on quality of life: a randomized controlled trial. <b>2013</b> , 149, 584-91		37
670	Systematic review of UV-based therapy for psoriasis. <b>2013</b> , 14, 87-109		62
669	Oral fumaric acid esters for psoriasis. <b>2013</b> ,		2
668	Treatment of psoriasis and psoriatic arthritis. <b>2013</b> , 27 Suppl 1, 3-12		39
667	Global epidemiology of psoriasis: a systematic review of incidence and prevalence. <b>2013</b> , 133, 377-85		1392
666	Using a single product (calcipotriene/betamethasone topical suspension) vs multiple products to manage body and scalp psoriasis: comparisons in resource utilization and costs. <b>2013</b> , 16, 1405-13		3

665	Eribulin in cutaneous breast cancer metastasis treatment: clinical activity and symptom control. <b>2013</b> , 9, 1841-8		3
664	The role of focal infections in the pathogenesis of psoriasis and chronic urticaria. <b>2013</b> , 30, 77-84		14
663	Psoriasis Hastaların Hastalıklarıyla İlgili Bilgi, İnanç ve Tutumları <b>2013</b> , 47, 103-108		2
662	IL-17 targeted therapies for psoriasis. <b>2013</b> , 22, 993-1005		114
661	Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis. <b>2013</b> , 133, 2340-2346		172
660	How psoriasis patients perceive, obtain, and use biologic agents: Survey from an academic medical center. <b>2013</b> , 24, 13-24		19
659	Comorbidities of psoriasis. <b>2013</b> , 8, 277-290		1
658	'On the surface': a qualitative study of GPs' and patients' perspectives on psoriasis. <b>2013</b> , 14, 158		42
657	Measurement of health-related quality of life in dermatological research and practice: outcome of the EADV Taskforce on Quality of Life. <b>2013</b> , 27, 1195-203		51
656	Satisfaction with treatment among patients with psoriasis: a web-based survey study. <i>British Journal of Dermatology</i> , <b>2013</b> , 169, 398-405	4	57
655	Psoriasis uncovered--measuring burden of disease impact in a survey of Australians with psoriasis. <b>2013</b> , 54 Suppl 1, 1-6		17
654	Treatment goals for moderate to severe psoriasis: an Australian consensus. <b>2013</b> , 54, 148-54		36
653	Assessment of female sexual function in patients with psoriasis. <b>2013</b> , 10, 1545-8		21
652	Qualitative assessment of the content validity of the Dermatology Life Quality Index in patients with moderate to severe psoriasis. <b>2013</b> , 24, 50-9		17
651	Etanercept for the treatment of psoriasis. <b>2013</b> , 8, 357-372		4
650	Patients' narratives. <b>2013</b> , 44, 145-57		1
649	Vascular endothelial growth factor inhibitors: investigational therapies for the treatment of psoriasis. <b>2013</b> , 6, 233-44		23
648	Immunotargeting in the management of psoriasis. <b>2013</b> , 2, 51-60		2

647	Clinical, Quality of Life, Patient Adherence, and Safety Outcomes of Short-Course (12 Weeks) Treatment with Cyclosporine in Patients with Severe Psoriasis (the Practice Study). <b>2013</b> , 25, 28-35	5
646	Psoriasis: Impact on Quality of Life. <b>2013</b> , 19a, 16-20	
645	Tracking dynamic microvascular changes during healing after complete biopsy punch on the mouse pinna using optical microangiography. <b>2013</b> , 8, e57976	23
644	Promising new treatments for psoriasis. <b>2013</b> , 2013, 980419	28
643	Tumor Necrosis Factor- $\alpha$ Triad: Psoriasis, Cardiovascular Disease, and Depression. <b>2013</b> , 19a, 41-49	2
642	The Skin and Viral Liver Disease. <b>2013</b> ,	
641	Quality of Life in Psoriasis. <b>2013</b> ,	1
640	Efficacy and cost-efficacy of biologic therapies for moderate to severe psoriasis: a meta-analysis and cost-efficacy analysis using the intention-to-treat principle. <b>2014</b> , 2014, 862851	23
639	Epidemiology and treatment of psoriasis: a Chinese perspective. <i>Psoriasis: Targets and Therapy</i> , <b>2014</b> , 37	2.4 0
638	Impact of postthyroidectomy scar on the quality of life of thyroid cancer patients. <b>2014</b> , 26, 693-9	122
637	Interleukin-17 in Atherosclerosis: Commentary. <b>2014</b> , 20a, 59-59	
636	Dermatology Trials. <b>2014</b> ,	
635	Quality of life in psoriasis patients. <b>2014</b> , 14, 559-68	63
634	'In someone's clinic but not in mine'--clinicians' views of supporting lifestyle behaviour change in patients with psoriasis: a qualitative interview study. <i>British Journal of Dermatology</i> , <b>2014</b> , 171, 1116-22 4	22
633	Patient reports of the frequency and severity of adverse reactions associated with biological agents prescribed for psoriasis in Brazil. <b>2014</b> , 13, 1155-63	6
632	Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis. <b>2014</b> , 1, 1-20	20
631	The impact of fingernail psoriasis on patients' health-related and disease-specific quality of life. <b>2014</b> , 229, 76-82	14
630	Fumaderm $\square$ in daily practice for psoriasis: dosing, efficacy and quality of life. <i>British Journal of Dermatology</i> , <b>2014</b> , 171, 1197-205	4 25

629	Implementing best practice in psoriasis: a Nordic expert group consensus. <b>2014</b> , 94, 547-52	7
628	Effectiveness of interdisciplinary vs. dermatological care of moderate-to-severe psoriasis: a pragmatic randomised controlled trial. <b>2014</b> , 94, 192-7	11
627	Diagnosis and treatment of adults with scalp psoriasis. <b>2014</b> , 28, 35-9	3
626	Membrane and soluble Toll-like receptor 2 in patients with psoriasis treated by Goeckerman therapy. <b>2014</b> , 53, e512-7	7
625	Chronic disease influences over 40 major life-changing decisions (MLCDs): a qualitative study in dermatology and general medicine. <b>2014</b> , 28, 1344-55	12
624	Population exposure-response model to support dosing evaluation of ixekizumab in patients with chronic plaque psoriasis. <b>2014</b> , 54, 1117-24	17
623	Real-life effectiveness of once-daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: 4- and 12-week interim results from the PRO-long study. <b>2014</b> , 28, 1723-31	16
622	Biologics are more potent than other treatment modalities for improvement of quality of life in psoriasis patients. <b>2014</b> , 41, 686-9	19
621	. <b>2014</b> , 5, 58-64	2
620	Impacto de la psoriasis en la sexualidad de los pacientes. <b>2014</b> , 29, 632-636	
619	Quality of life and related factors in a cohort of plaque-type psoriasis patients in La Coruña, Spain. <b>2014</b> , 53, e507-11	16
618	Psychodermatological aspects of atopic dermatitis. <i>British Journal of Dermatology</i> , <b>2014</b> , 170 Suppl 1, 38-43	4 58
617	Comorbidities and health-related quality of life in Spanish patients with moderate to severe psoriasis: a cross-sectional study (Arizona study). <b>2014</b> , 41, 673-8	42
616	Pooled safety analysis of calcipotriol plus betamethasone dipropionate gel for the treatment of psoriasis on the body and scalp. <b>2014</b> , 28 Suppl 2, 10-21	13
615	Efficacious treatment of psoriasis with low-dose and intermittent cyclosporin microemulsion therapy. <b>2014</b> , 41, 377-81	7
614	Social problem-solving, perceived stress, negative life events, depression and life satisfaction in psoriasis. <b>2014</b> , 28, 1553-9	22
613	The Psoriasis Symptom Diary: development and content validity of a novel patient-reported outcome instrument. <b>2014</b> , 53, 714-22	39
612	The experience of having psoriasis through the lens of the International Classification of Functioning, Disability and Health (ICF). <b>2014</b> , 55, 241-9	1

611	Hope as a Psychological Factor Affecting Quality of Life in Patients With Psoriasis. <b>2014</b> , 9, 273-283		9
610	Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. <b>2014</b> , 74, 423-41		158
609	In psoriasis, levels of hope and quality of life are linked. <b>2014</b> , 306, 661-6		26
608	Treatment sequencing after failure of the first biologic in cost-effectiveness models of psoriasis: a systematic review of published models and clinical practice guidelines. <b>2014</b> , 32, 395-409		19
607	Nociceptive sensory neurons drive interleukin-23-mediated psoriasiform skin inflammation. <b>2014</b> , 510, 157-61		308
606	Research gaps in psoriasis: opportunities for future studies. <i>Journal of the American Academy of Dermatology</i> , <b>2014</b> , 70, 146-67	4.5	85
605	Identifying individual psychosocial and adherence support needs in patients with psoriasis: a multinational two-stage qualitative and quantitative study. <b>2014</b> , 28, 763-70		61
604	Beneath the surface: dermatology and psychiatry. <b>2014</b> , 18, 16-18		1
603	Perceived impact of psoriasis on leisure-time activities. <b>2014</b> , 24, 224-8		13
602	Handbook of Lasers in Dermatology. <b>2014</b> ,		8
601	Patient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting. <i>Journal of the American Academy of Dermatology</i> , <b>2014</b> , 71, 633-41	4.5	51
600	Advances in Psoriasis. <b>2014</b> ,		3
599	Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial. <b>2014</b> , 384, 2036-45		89
598	The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis. <b>2014</b> , 134, 1542-1551		206
597	Treatment costs of psoriasis in a tertiary-level clinic. <b>2014</b> , 14, 344		9
596	Effects of briakinumab treatment for moderate to severe psoriasis on health-related quality of life and work productivity and activity impairment: results from a randomized phase III study. <b>2014</b> , 28, 790-8		17
595	Infliximab treatment of psoriasis in supervised infusion centers: case management experience. <b>2014</b> , 15 Suppl 1, S17-24		22
594	Development and validation of a new instrument to measure health-related quality of life in patients with psoriatic arthritis: the VITACORA-19. <b>2014</b> , 41, 2008-17		10

593	Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. <i>Journal of the American Academy of Dermatology</i> , <b>2014</b> , 70, 871-81.e1-30	4-5	332
592	Treatment of psoriasis: focus on clinic-based management with infliximab. <b>2014</b> , 15 Suppl 1, S5-16		3
591	Is dietary supplementation more common among adults with psoriasis? Results from the National Health and Nutrition Examination Survey. <b>2014</b> , 22, 159-65		6
590	Caracterizaci3n de estudios sobre calidad de vida relacionada con la salud en personas con psoriasis: revisi3n sistem3tica 2003-2013. <b>2014</b> , 21, 35-41		
589	Nail Psoriasis, the unknown burden of disease. <b>2014</b> , 28, 1690-5		43
588	Palmoplantar psoriasis is associated with greater impairment of health-related quality of life compared with moderate to severe plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2014</b> , 71, 623-32	4-5	57
587	Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis. <b>2014</b> , 28, 192-203		49
586	Adherence to guidelines in the use of biological agents to treat psoriasis in Brazil. <b>2014</b> , 4, e004179		6
585	Self-medication of psoriasis in southwestern China. <b>2014</b> , 228, 368-74		5
584	Real-life effectiveness of once-daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: final analysis of the 52-week PRO-long study. <b>2015</b> , 29, 2349-55		27
583	IgA nephropathy and psoriatic arthritis that improved with steroid pulse therapy and mizoribine in combination with treatment for chronic tonsillitis and epipharyngitis. <b>2015</b> , 54, 1085-90		8
582	Ustekinumab treatment in patients with psoriasis undergoing hemodialysis. <b>2015</b> , 42, 731-4		9
581	The Worst Itch Numeric Rating Scale for patients with moderate to severe plaque psoriasis or psoriatic arthritis. <b>2015</b> , 54, 715-22		26
580	Quality of life: a research gap in teledermatology. <b>2015</b> , 54, 1124-8		13
579	SF-36 healthy survey on psoriasis quality-of-life: a study of 414 Taiwanese patients. <b>2015</b> , 42, 159-65		17
578	Patient-reported outcome measures in psoriasis: the good, the bad and the missing!. <i>British Journal of Dermatology</i> , <b>2015</b> , 172, 1210-21	4	34
577	Consumer Quality Index Chronic Skin Disease (CQI-CSD): a new instrument to measure quality of care from the patient's perspective. <i>British Journal of Dermatology</i> , <b>2015</b> , 173, 1032-40	4	3
576	Risk of depression in women with psoriasis: a cohort study. <i>British Journal of Dermatology</i> , <b>2015</b> , 173, 975-80	4	55

575	Chronic stress experience and burnout syndrome have appreciable influence on health-related quality of life in patients with psoriasis. <b>2015</b> , 29, 1898-904	21
574	Oral fumaric acid esters for psoriasis. <b>2015</b> , CD010497	13
573	Comparison of three methods for measuring psoriasis severity in clinical studies (Part 2 of 2): use of quality of life to assess construct validity of the Lattice System Physician's Global Assessment, Psoriasis Area and Severity Index and Static Physician's Global Assessment. <b>2015</b> , 29, 1415-20	14
572	Patients with psoriasis have insufficient knowledge of their risk of atherothrombotic disease and metabolic syndrome. <b>2015</b> , 40, 600-4	12
571	Dermatology Trials. <b>2015</b> , 1-7	
570	Economic and Comorbidity Burden Among Patients with Moderate-to-Severe Psoriasis. <b>2015</b> , 21, 874-88	34
569	A study of awareness and screening behavior of cardiovascular risk factors in patients with psoriasis and dermatologists. <b>2015</b> , 27, 59-65	4
568	A systematic literature review to compare quality of life in psoriasis with other chronic diseases using EQ-5D-derived utility values. <b>2015</b> , 6, 167-77	61
567	Psoriasis in Children: A Review. <b>2015</b> , 11, 10-26	22
566	Distribution pattern of psoriasis, anxiety and depression as possible causes of sexual dysfunction in patients with moderate to severe psoriasis. <b>2015</b> , 90, 338-45	29
565	Quality of life and psychosocial aspects in Greek patients with psoriasis: a cross-sectional study. <b>2015</b> , 90, 841-5	25
564	Acquired latent tuberculosis infection in psoriasis patients treated with etanercept in the People's Republic of China. <b>2015</b> , 9, 5591-4	1
563	Indoor salt water baths followed by artificial ultraviolet B light for chronic plaque psoriasis. <b>2015</b> ,	1
562	Exploring the Physiological Link between Psoriasis and Mood Disorders. <b>2015</b> , 2015, 409637	37
561	The Correlation between the Dermatology Life Quality Index and the Psoriasis Area Severity Index. <b>2015</b> , 1, 26-30	
560	A pilot study examining mindfulness-based cognitive therapy in psoriasis. <b>2015</b> , 20, 121-7	52
559	Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. <b>2015</b> , 386, 552-61	279
558	Influence of Psoriasis on Household Chores and Time Spent on Skin Care at Home: A Questionnaire Study. <b>2015</b> , 5, 107-16	7

557	Perceptions on the Psychological Impact of Facial Erythema Associated with Rosacea: Results of International Survey. <b>2015</b> , 5, 117-27		34
556	Psoriasis. <b>2015</b> , 386, 983-94		1181
555	Fumaric acid esters in the management of psoriasis. <i>Psoriasis: Targets and Therapy</i> , <b>2015</b> , 5, 9-23	2.4	19
554	Register-Based Evaluation of Relative Effectiveness of New Therapies: Biologics Versus Conventional Agents in Treatment of Psoriasis in Sweden. <b>2015</b> , 29, 389-98		7
553	Retreatment in patients with psoriasis achieving response with etanercept after relapse due to treatment interruption: results from the CRYSTEL study. <b>2015</b> , 29, 468-73		10
552	Systematic review of cost-effectiveness analyses of treatments for psoriasis. <b>2015</b> , 33, 327-40		17
551	Fatigue in psoriasis: a phenomenon to be explored. <i>British Journal of Dermatology</i> , <b>2015</b> , 172, 1196-203	4	22
550	Efficacy, tolerability and safety of switching from etanercept to infliximab for the treatment of moderate-to-severe psoriasis: A multicenter, open-label trial (TANGO). <b>2015</b> , 26, 304-11		15
549	Effect of biologics on depressive symptoms in patients with psoriasis: a systematic review. <b>2015</b> , 29, 1063-70		59
548	Epigenetics in Psoriasis. <b>2015</b> , 227-248		1
547	Effectiveness and safety of adalimumab in treating moderate to severe psoriasis patients with psoriatic arthritis in Taiwan. <b>2015</b> , 33, 119-123		6
546	Psoriasis: classical and emerging comorbidities. <b>2015</b> , 90, 9-20		160
545	Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial. <i>British Journal of Dermatology</i> , <b>2015</b> , 172, 1395-406	4	106
544	Nail psoriasis as a predictor of the development of psoriatic arthritis. <b>2015</b> , 106, 452-7		43
543	A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis. <b>2015</b> , 373, 136-44		212
542	Treating Psoriasis During Pregnancy: Safety and Efficacy of Treatments. <b>2015</b> , 16, 389-98		16
541	Quantifying harmful effects of psoriatic diseases on quality of life: Cardio-metabolic outcomes in psoriatic arthritis study (COMPASS). <b>2015</b> , 44, 641-5		11
540	EPIMAG: International Cross-Sectional Epidemiological Psoriasis Study in the Maghreb. <b>2015</b> , 231, 134-44		15



539	Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. <b>2015</b> , 386, 541-51		576
538	Nail psoriasis as a predictor of the development of psoriatic arthritis. <b>2015</b> , 106, 452-457		0
537	A Web-based, educational, quality-of-life intervention for patients with a chronic skin disease: feasibility and acceptance in routine dermatological practice. <b>2015</b> , 95, 51-6		4
536	Resource use in patients with psoriasis after the introduction of biologics in Sweden. <b>2015</b> , 95, 156-61		9
535	Treatment goals for psoriasis: Should PASI 90 become the standard of care?. <b>2015</b> , 106, 155-157		1
534	Genital psoriasis is associated with significant impairment in quality of life and sexual functioning. <i>Journal of the American Academy of Dermatology</i> , <b>2015</b> , 72, 978-83	4.5	103
533	Role of skin biopsy in papulosquamous lesions— comparative study. <b>2015</b> , 24, 1205-1209		2
532	Epidemiology of Chronic Pruritus: Where Have We Been and Where Are We Going?. <b>2015</b> , 4, 20-29		17
531	Quality of life of psoriatic patients evaluated by a new psychometric assessment tool: PsoDisk. <b>2015</b> , 25, 64-9		6
530	Psoriasis and the Risk of Major Cardiovascular Events: Cohort Study Using the Clinical Practice Research Datalink. <b>2015</b> , 135, 2189-2197		96
529	Elevated prevalence of Type D (distressed) personality in moderate to severe psoriasis is associated with mood status and quality of life impairment: a comparative pilot study. <b>2015</b> , 29, 1710-7		14
528	Clinical symptoms and self-reported disease severity among patients with psoriasis - Implications for psoriasis management. <b>2015</b> , 26, 514-9		11
527	Systemic pharmacological treatments for chronic plaque psoriasis. <b>2015</b> ,		4
526	Treatment goals for psoriasis: Should PASI 90 become the standard of care?. <b>2015</b> , 106, 155-7		35
525	Efficacy and safety of emerging immunotherapies in psoriasis. <b>2015</b> , 7, 119-33		15
524	Psoriasis and Cardiovascular Disease. <b>2015</b> , 99, 1227-42		21
523	The Budget Impact of Biosimilar Infliximab (Remsima® ) for the Treatment of Autoimmune Diseases in Five European Countries. <b>2015</b> , 32, 742-56		107
522	Qualité de vie et activité professionnelle des patients atteints de psoriasis au centre tunisien. <b>2015</b> , 76, 439-448		2

521	Clinical Outcome and Quality of Life After a Multimodal Therapy Approach to Ear Keloids. <b>2015</b> , 17, 333-9		17
520	Restless legs syndrome in psoriasis: an unexpected comorbidity. <b>2015</b> , 25, 255-60		10
519	Acupuncture for psoriasis: protocol for a systematic review. <b>2015</b> , 5, e007526		4
518	Health care resource use, productivity, and costs among patients with moderate to severe plaque psoriasis in the United States. <i>Journal of the American Academy of Dermatology</i> , <b>2015</b> , 73, 585-593.e3	4-5	36
517	Decision for biological treatment in real life is more strongly associated with the Psoriasis Area and Severity Index (PASI) than with the Dermatology Life Quality Index (DLQI). <b>2015</b> , 29, 452-6		29
516	Sexual dysfunction in psoriasis: a systematic review. <b>2015</b> , 29, 649-55		44
515	Psoriasis treatment and management - a systematic review of full economic evaluations. <i>British Journal of Dermatology</i> , <b>2015</b> , 172, 574-83	4	10
514	Psoriasis and the life cycle of persistent life effects. <b>2015</b> , 33, 25-39		23
513	Ten years on: the impact of biologics on the practice of dermatology. <b>2015</b> , 33, 111-25		14
512	Psoriasis and sport: a new ally?. <b>2015</b> , 29, 515-20		28
511	Quality of Life and Psychosocial Needs of Children Suffering from Chronic Skin Diseases. <b>2016</b> , 52, 133-148		5
510	Psychological Interventions in the Treatment of Chronic Itch. <b>2016</b> , 96, 157-61		59
509	Management of scalp psoriasis: current perspectives. <i>Psoriasis: Targets and Therapy</i> , <b>2016</b> , 6, 33-40	2.4	4
508	Assessment and monitoring of biologic drug adverse events in patients with psoriasis. <i>Psoriasis: Targets and Therapy</i> , <b>2016</b> , 6, 41-54	2.4	3
507	Engineering the tissue-wound interface: Harnessing topography to direct wound healing. <b>2016</b> , 253-275		3
506	Risk of Cardiovascular Outcomes among Psoriasis Patients Treated with Biologics and Other Systemic Agents. <b>2016</b> , 1, 128-137		3
505	Radiographic and functional outcomes after displaced intra-articular calcaneal fractures: a comparative cohort study among the traditional open technique (ORIF) and percutaneous surgical procedures (PS). <b>2016</b> , 11, 92		24
504	Psoriasis and Psychological Comorbidities. <b>2016</b> , 1, 80-85		2

503	Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: a systematic review of the literature. <b>2016</b> , 10, 2357-2367		50
502	Economic Burden of Psoriasis and Potential Cost Offsets with Biologic Treatment: A Swedish Register Analysis. <b>2016</b> , 96, 651-7		11
501	PGRN Suppresses Inflammation and Promotes Autophagy in Keratinocytes Through the Wnt/ $\beta$ Catenin Signaling Pathway. <b>2016</b> , 39, 1387-94		31
500	Health-related quality of life in patients with psoriasis: a systematic review of the European literature. <b>2016</b> , 25, 2739-2754		34
499	Psoriasis and New-onset Depression: A Danish Nationwide Cohort Study. <b>2016</b> , 96, 39-42		39
498	Topical treatments for scalp psoriasis. <b>2016</b> , 2, CD009687		13
497	Risk of self-harm and nonfatal suicide attempts, and completed suicide in patients with psoriasis: a population-based cohort study. <i>British Journal of Dermatology</i> , <b>2016</b> , 175, 493-500	4	33
496	Secukinumab treatment of plaque psoriasis shows early improvement in DLQI response - results of a phase II regimen-finding trial. <b>2016</b> , 30, 645-9		13
495	Factors influencing patient satisfaction: assessment in outpatients in dermatology department. <b>2016</b> , 30, 1823-1828		13
494	Clinical, ultrasound, and videodermatoscopy monitoring of psoriatic patients following biological treatment. <b>2016</b> , 22, 341-8		16
493	Clinical meaningfulness of complete skin clearance in psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2016</b> , 75, 77-82.e7	4.5	65
492	Nail Psoriasis: A Review of Treatment Options. <b>2016</b> , 76, 675-705		74
491	Health state utility, willingness to pay, and quality of life among Taiwanese patients with psoriasis. <b>2016</b> , 34, 185-191		12
490	Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2016</b> , 75, 1162-1170.e3	4.5	41
489	Combination Therapy of Etanercept and Fumarates versus Etanercept Monotherapy in Psoriasis: A Randomized Exploratory Study. <b>2016</b> , 232, 407-14		8
488	Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials. <i>Journal of the American Academy of Dermatology</i> , <b>2016</b> , 75, 1156-1161	4.5	28
487	Psychometric properties of the Itch Numeric Rating Scale in patients with moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , <b>2016</b> , 175, 157-62	4	51
486	The role of personal models in clinical management: Exploring health care providers' beliefs about psoriasis. <b>2016</b> , 21, 114-34		7

485	TUR-PSO: A cross-sectional, study investigating quality of life and treatment status of psoriasis patients in Turkey. <b>2016</b> , 43, 298-304	10
484	DLQI as a major criterion for introduction of systemic agents in patients with mild psoriasis. <b>2016</b> , 30, 1961-1964	16
483	No meaningful association between suicidal behavior and the use of IL-17A-neutralizing or IL-17RA-blocking agents. <b>2016</b> , 15, 1653-1659	32
482	Values and costs in the management of psoriasis. <b>2016</b> , 27, 393-4	
481	Associations of the quality of life and psychoemotional state with sociodemographic factors in patients with psoriasis. <b>2016</b> , 52, 238-243	15
480	Neutrophil extracellular trap formation is increased in psoriasis and induces human $\alpha$ -defensin-2 production in epidermal keratinocytes. <b>2016</b> , 6, 31119	88
479	Clinical efficacy of platelet rich plasma in combination with methotrexate in chronic plaque psoriatic patients. <b>2016</b> , 29, 446-450	17
478	A systematic review on methods used to evaluate patient preferences in psoriasis treatments. <b>2016</b> , 30, 1454-64	23
477	Wie auf einem Nagelbrett liegen. <b>2016</b> , 15, 105-109	
476	Body Region Involvement and Quality of Life in Psoriasis: Analysis of a Randomized Controlled Trial of Adalimumab. <b>2016</b> , 17, 691-699	15
475	The Annual Economic Burden of Psoriasis. <b>2016</b> , 1, 112-122	
474	Review of Available and Investigational Biologics and Non-Biologic Small Molecules for the Treatment of Plaque Psoriasis. <b>2016</b> , 2, 11-21	3
473	Depression and Insomnia in Patients With Psoriasis and Psoriatic Arthritis Taking Tumor Necrosis Factor Antagonists. <b>2016</b> , 95, e3816	34
472	Factors Predicting Testing and Treatment of Iron Deficiency in a Nationwide Cohort of Anemic UC Patients. <b>2016</b> , 22, 2894-2901	7
471	Extent of misconceptions, negative prejudices and discriminatory behaviour to psoriasis patients in France. <b>2016</b> , 30, 650-4	19
470	A prospective cross-sectional study of anxiety and depression in patients with psoriasis in Singapore. <b>2016</b> , 30, 1159-64	24
469	Prevalence and Associated Factors of Erectile Dysfunction in Patients With Moderate to Severe Psoriasis and Healthy Population: A Comparative Study Considering Physical and Psychological Factors. <b>2016</b> , 45, 2047-2055	13
468	Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. <b>2016</b> , 375, 345-56	505

467	Communicating Cardiovascular Disease Risk to People with Psoriasis: What Techniques do Practitioners Use?. <b>2016</b> , 23, 168-78	5
466	Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective. <b>2016</b> , 6, 151-67	4
465	Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?. <b>2016</b> , 46, 291-304	84
464	Durable dermatology life quality index improvements in patients on biologics associated with psoriasis areas and severity index: a longitudinal study. <b>2016</b> , 57, e72-5	8
463	Translating psoriasis guidelines into practice: Important gaps revealed. <i>Journal of the American Academy of Dermatology</i> , <b>2016</b> , 74, 544-51	4-5 3
462	Quality of life in psoriasis. <b>2016</b> , 101-116	1
461	Assessment of Quality of Life in Patients With Skin Disorders Undergoing Ayurvedic Panchakarma (Biopurification) as Management. <b>2016</b> , 21, 215-20	3
460	Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double-blind, phase 3 study. <b>2016</b> , 43, 869-80	63
459	Novel investigational vascular endothelial growth factor (VEGF) receptor antagonists for psoriasis. <b>2016</b> , 25, 455-62	17
458	Relationship between Histological and Clinical Course of Psoriasis: A Pilot Investigation by Reflectance Confocal Microscopy during Goeckerman Treatment. <b>2016</b> , 29, 47-54	11
457	The Role of Acupuncture in Pain Management. <b>2016</b> , 20, 22	49
456	Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis: Analysis of Results From 3 Randomized Phase 3 Clinical Trials. <b>2016</b> , 152, 661-9	37
455	Handbook of Psoriasis and Psoriatic Arthritis. <b>2016</b> ,	2
454	Patient-relevant treatment goals in psoriasis. <b>2016</b> , 308, 69-78	67
453	The role of ferric carboxymaltose in the treatment of iron deficiency anemia in patients with gastrointestinal disease. <b>2016</b> , 9, 76-85	11
452	Experience and challenges for biologic use in the treatment of moderate-to-severe psoriasis in Africa and the Middle East region. <b>2017</b> , 28, 129-135	4
451	Psoriasis and the liver: problems, causes and course. <b>2017</b> , 58, 194-199	9
450	Soccer helps in controlling the development of psoriasis in Italian second league players. <b>2017</b> , 31, e212-e214	4

449	Toward a better understanding of social anxiety and depression in psoriasis patients: The role of determinants, mediators, and moderators. <b>2017</b> , 94, 32-38		30
448	Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept. <i>Journal of the American Academy of Dermatology</i> , <b>2017</b> , 76, 655-661	4.5	20
447	Psoriasis and cardiovascular events: updating the evidence. <b>2017</b> , 309, 225-228		26
446	Psoriasis and comorbid diseases: Epidemiology. <i>Journal of the American Academy of Dermatology</i> , <b>2017</b> , 76, 377-390	4.5	412
445	An exploratory study using framework analysis to investigate health-seeking behaviour in patients with psoriasis. <i>British Journal of Dermatology</i> , <b>2017</b> , 177, 742-750	4	9
444	Aquaporins. <b>2017</b> ,		11
443	Aquaporins in the Skin. <b>2017</b> , 969, 173-191		16
442	Incremental burden of cardiovascular comorbidity and psoriatic arthritis among adults with moderate-to-severe psoriasis in five European countries. <b>2017</b> , 31, 1316-1323		17
441	Psoriasis, Depression, and Inflammatory Overlap: A Review. <b>2017</b> , 18, 613-620		37
440	Dermatological comorbidity in psoriasis: results from a large-scale cohort of employees. <b>2017</b> , 309, 349-356		13
439	Paeoniflorin suppressed IL-22 via p38 MAPK pathway and exerts anti-psoriatic effect. <b>2017</b> , 180, 17-22		26
438	Update on Comorbidities in Psoriasis. <b>2017</b> , 6, 129-136		1
437	Immunopathogenesis of Psoriasis. <b>2017</b> , 373-395		2
436	From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2017</b> , 76, 290-298	4.5	90
435	Assessment of the psychometric properties of the EQ-5D-3L and EQ-5D-5L instruments in psoriasis. <b>2017</b> , 309, 357-370		27
434	Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. <b>2017</b> , 390, 276-288		302
433	Impact of ixekizumab treatment on skin-related personal relationship difficulties in moderate-to-severe psoriasis patients: 12-week results from two Phase 3 trials. <b>2017</b> , 31, 1867-1875		9
432	Minimal disease activity in patients with psoriatic arthritis treated with ustekinumab: results from a 24-week real-world study. <b>2017</b> , 36, 1589-1593		11

431	Comparative effectiveness of biological therapies on improvements in quality of life in patients with psoriasis. <i>British Journal of Dermatology</i> , <b>2017</b> , 177, 1410-1421	4	19
430	Treating Psoriasis and Psoriatic Arthritis: Position Paper on Applying the Treat-to-target Concept to Canadian Daily Practice. <b>2017</b> , 44, 519-534		14
429	Clinical trials in dermatology. <b>2017</b> , 3, 180-183		4
428	A Novel Model for Predicting Incident Moderate to Severe Anemia and Iron Deficiency in Patients with Newly Diagnosed Ulcerative Colitis. <b>2017</b> , 62, 1295-1304		3
427	Rapid improvements in health-related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER-2 and UNCOVER-3. <b>2017</b> , 31, 1483-1490		27
426	Increasing prevalence but not incidence of psoriasis in the U.K. <i>British Journal of Dermatology</i> , <b>2017</b> , 176, 568-569	4	
425	Prevalence of weight loss attempts and behaviors used by individuals with psoriasis in the United States population. <b>2017</b> , 28, 515-519		2
424	Could maternal stress increase the risk of developing psoriasis in the offspring?. <i>British Journal of Dermatology</i> , <b>2017</b> , 176, 569-570	4	
423	A cross-sectional survey of the nature and correlates of sleep disturbance in people with psoriasis. <i>British Journal of Dermatology</i> , <b>2017</b> , 177, 1052-1059	4	30
422	The potential utility of tildrakizumab: an interleukin-23 inhibitor for the treatment of psoriasis. <b>2017</b> , 26, 243-249		4
421	Management of Moderate to Severe Plaque Psoriasis: The Emerging Role of IL-17 Inhibition. <b>2017</b> , 21, 25-40S		5
420	Clinical efficacy and quality of life under micronutrients in combination with methotrexate therapy in chronic plaque of psoriatic patients. <b>2017</b> , 35, 187-194		1
419	Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis. <b>2017</b> , 13, 2247-2259		56
418	Moderate Psoriasis: A Proposed Definition. <b>2017</b> , 108, 911-917		26
417	Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients. <b>2017</b> , 26, 3409-3419		37
416	Psychosocial morbidity in skin disease. <b>2017</b> , 78, C82-C86		9
415	A review article on brodalumab in the treatment of moderate-to-severe plaque psoriasis. <b>2017</b> , 9, 963-978		5
414	Serious infections among a large cohort of subjects with systemically treated psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2017</b> , 77, 838-844	4.5	21

413	Psoriasis pathogenesis and the development of novel targeted immune therapies. <b>2017</b> , 140, 645-653		400
412	Quality of life in patients with vitiligo using the Short Form-36. <i>British Journal of Dermatology</i> , <b>2017</b> , 177, 1764-1766	4	2
411	Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis: Subgroup analysis of Latin American patients in the phase 3 randomized UNCOVER-3 study. <b>2017</b> , 108, 550-563		7
410	Managing Mild-to-Moderate Psoriasis in Elderly Patients: Role of Topical Treatments. <b>2017</b> , 34, 583-588		8
409	Non-thermal atmospheric plasma ameliorates imiquimod-induced psoriasis-like skin inflammation in mice through inhibition of immune responses and up-regulation of PD-L1 expression. <b>2017</b> , 7, 15564		15
408	Moderate Psoriasis: A Proposed Definition. <b>2017</b> , 108, 911-917		5
407	Bioactive Polyphenols for Diabetes and Inflammation in Psoriasis Disease. <b>2017</b> , 231-268		4
406	Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis: Subgroup analysis of Latin American patients in the phase 3 randomized UNCOVER-3 study. <b>2017</b> , 108, 550-563		
405	Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials. <b>2017</b> , 7, 281-292		41
404	Tight controlled dose reduction of biologics in psoriasis patients with low disease activity: a randomized pragmatic non-inferiority trial. <b>2017</b> , 17, 6		9
403	Clear or almost clear skin improves the quality of life in patients with moderate-to-severe psoriasis: a systematic review and meta-analysis. <b>2017</b> , 31, 213-220		43
402	Patients' perspectives in the management of psoriasis: the Italian results of the Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey. <b>2017</b> , 28, 390-393		7
401	Sexual health and quality of life are impaired in hidradenitis suppurativa: a multicentre cross-sectional study. <i>British Journal of Dermatology</i> , <b>2017</b> , 176, 1042-1047	4	61
400	FamilyPso - a new questionnaire to assess the impact of psoriasis on partners and family of patients. <b>2017</b> , 31, 127-134		9
399	Incidence, prevalence and mortality of patients with psoriasis: a U.K. population-based cohort study. <i>British Journal of Dermatology</i> , <b>2017</b> , 176, 650-658	4	115
398	Socioeconomic and sociocultural determinants of psychological distress and quality of life among patients with psoriasis in a selected multi-ethnic Malaysian population. <b>2017</b> , 22, 184-195		13
397	Early clinical response to tofacitinib treatment as a predictor of subsequent efficacy: Results from two phase 3 studies of patients with moderate-to-severe plaque psoriasis. <b>2017</b> , 28, 3-7		6
396	L'ëgora du psoriasis : histoire, actualitë et questionnements. <b>2017</b> , 144 Suppl 3, IIS23-IIS28		0



395	Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. <b>2017</b> , 12, CD011535	69
394	Behandeling met biologicals in de dermatologie. <b>2017</b> , 34, 129	
393	Psoriasis and Depression: A Comprehensive Review for Clinicians. <b>2017</b> , 2, 47-56	1
392	Unerwünschte Wirkungen von Biologika bei Psoriasis. <b>2017</b> , 5, 195-199	0
391	Patient-reported Outcomes and Clinical Response in Patients with Moderate-to-severe Plaque Psoriasis Treated with Tonsillectomy: A Randomized Controlled Trial. <b>2017</b> , 97, 340-345	17
390	Determinants of Psychosocial Health in Psoriatic Patients: A Multi-national Study. <b>2017</b> , 97, 1182-1188	17
389	Burden of Keloid Disease: A Cross-sectional Health-related Quality of Life Assessment. <b>2017</b> , 97, 225-229	47
388	Management of the psychological comorbidities of dermatological conditions: practitioners' guidelines. <b>2017</b> , 10, 117-132	14
387	Greater Efficacy with Secukinumab Treatment is Associated with Greater Psoriasis Symptom Relief: Results from Secukinumab Clinical Trial Data. <b>2017</b> , 2, 73-80	1
386	Cardiovascular and Metabolic Diseases Comorbid with Psoriasis: Beyond the Skin. <b>2017</b> , 56, 1613-1619	39
385	The content validity of the PSS in patients with plaque psoriasis. <b>2017</b> , 1, 4	9
384	Prediction of NB-UVB phototherapy treatment response of psoriasis patients using data mining. <b>2017</b> ,	
383	Dynamic Balancing in Illness Coping: An Interpretative Phenomenological Analysis on the Lived Experience of Chinese Patients with Psoriasis. <b>2017</b> , 11,	1
382	Access Pathway Delays and Burden of Disease for Patients with Severe Chronic Skin Conditions Requiring Systemic and Biologic Therapies at an Irish Dermatology Centre. <b>2017</b> , 09,	
381	Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab. <b>2017</b> , 13, 315-323	16
380	How does stigma affect people with psoriasis?. <b>2017</b> , 34, 36-41	30
379	Associations between body mass index and severity of psoriasis. <b>2017</b> , 10, 493-498	6
378	Evaluation of fatigue and its correlation with quality of life index, anxiety symptoms, depression and activity of disease in patients with psoriatic arthritis. <b>2017</b> , 10, 155-163	22

377	Gender, Body Image and Social Support: Biopsychosocial Determinants of Depression Among Patients with Psoriasis. <b>2017</b> , 97, 91-97		24
376	Guselkumab for the Treatment of Psoriasis. <b>2018</b> , 32, 119-128		21
375	Prevalence and predictors of depressive symptoms among attendees of a tertiary care dermatology clinic in Muscat, Oman. <b>2018</b> , 57, 284-290		6
374	Guselkumab for the treatment of moderate-to-severe plaque psoriasis. <b>2018</b> , 11, 333-344		8
373	Correlating the Dermatology Life Quality Index and Skin Discoloration Impact Evaluation Questionnaire tools in disorders of hyperpigmentation. <b>2018</b> , 45, 361-362		11
372	The risk of cardiovascular events in psoriasis patients treated with tumor necrosis factor- $\alpha$ inhibitors versus phototherapy: An observational cohort study. <i>Journal of the American Academy of Dermatology</i> , <b>2018</b> , 79, 60-68	4.5	39
371	Determinants of quality of life and psychological status in adults with psoriasis. <b>2018</b> , 310, 443-451		25
370	Improvement of depressive symptoms in patients with moderate-to-severe psoriasis treated with ustekinumab: an open label trial validated using beck depression inventory, Hamilton depression rating scale measures and fluorodeoxyglucose (FDG) positron emission tomography (PET). <b>2018</b> , 33, 711-718		9
369	Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study. <b>2018</b> , 45, 529-539		51
368	Carboxytherapy for treatment of localized chronic plaque psoriasis: Clinical and histopathologic evaluation. <b>2018</b> , 17, 527-532		2
367	The role of adult attachment orientation and coping in psychological adjustment to living with skin conditions. <i>British Journal of Dermatology</i> , <b>2018</b> , 178, 1396-1403	4	3
366	Adherence to biologics in patients with psoriasis. <b>2018</b> , 14, 155-161		10
365	A multidimensional assessment of the burden of psoriasis: results from a multinational dermatologist and patient survey. <i>British Journal of Dermatology</i> , <b>2018</b> , 179, 173-181	4	38
364	The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis. <b>2018</b> , 29, 557-568		26
363	Soy Phosphatidylglycerol Reduces Inflammation in a Contact Irritant Ear Edema Mouse Model In Vivo. <b>2018</b> , 366, 1-8		10
362	Biosimilar Drugs for Psoriasis: Principles, Present, and Near Future. <b>2018</b> , 8, 173-194		32
361	Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry. <i>Journal of the American Academy of Dermatology</i> , <b>2018</b> , 78, 323-332	4.5	47
360	Epidemiological survey of patients with psoriasis in Matsumoto city, Nagano Prefecture, Japan. <b>2018</b> , 45, 314-317		7

359	Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3). <i>British Journal of Dermatology</i> , <b>2018</b> , 178, 674-681	4	57
358	Burden of chronic urticaria relative to psoriasis in five European countries. <b>2018</b> , 32, 282-290		19
357	Adverse Reactions to Biologics in Psoriasis. <b>2018</b> , 53, 1-14		11
356	Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey. <b>2018</b> , 31, e12565		3
355	Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR). <i>Journal of the American Academy of Dermatology</i> , <b>2018</b> , 78, 70-80	4.5	51
354	The journey of adult psoriasis patients towards biologics: past and present - Results from the BioCAPTURE registry. <b>2018</b> , 32, 615-623		15
353	Review of the mechanism of action of coal tar in psoriasis. <b>2018</b> , 29, 230-232		16
352	Impact of Disease Severity, Illness Beliefs, and Coping Strategies on Outcomes in Psoriatic Arthritis. <b>2018</b> , 70, 295-302		16
351	A case study of an interaction design approach to pervasive healthcare. <b>2018</b> ,		0
350	Tetrandrine inhibits the proliferation and cytokine production induced by IL-22 in HaCaT cells. <b>2018</b> , 46, 5210-5218		5
349	Secukinumab in the treatment of psoriasis: patient selection and perspectives. <i>Psoriasis: Targets and Therapy</i> , <b>2018</b> , 8, 75-82	2.4	10
348	Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date. <i>Psoriasis: Targets and Therapy</i> , <b>2018</b> , 8, 83-92	2.4	5
347	Impact of psoriasis in the quality of life of children, adolescents and their families: a cross-sectional study. <b>2018</b> , 93, 819-823		25
346	Urinary Orosomuroid A Potential Marker Of Inflammation In Psoriasis. <b>2018</b> , 15, 1113-1117		5
345	Disease Burden and Treatment Patterns of Psoriasis in Russia: A Real-World Patient and Dermatologist Survey. <b>2018</b> , 8, 581-592		5
344	Bridging the Gaps in the Care of Psoriasis and Psoriatic Arthritis: the Role of Combined Clinics. <b>2018</b> , 20, 76		15
343	The impact of genital psoriasis on quality of life: a systematic review. <i>Psoriasis: Targets and Therapy</i> , <b>2018</b> , 8, 41-47	2.4	14
342	Application of Photoacoustic Methods and Confocal Microscopy for Monitoring of Therapeutic Response in Plaque Psoriasis. <b>2018</b> , 31, 308-315		7

341	Long-term Impact of Ixekizumab on Psoriasis Itch Severity: Results from a Phase III Clinical Trial and Long-term Extension. <b>2018</b> , 98, 98-102	12
340	Positive effects of hydrogen-water bathing in patients of psoriasis and parapsoriasis en plaques. <b>2018</b> , 8, 8051	21
339	Inflammation: A Contributor to Depressive Comorbidity in Inflammatory Skin Disease. <b>2018</b> , 31, 246-251	35
338	Real-world health outcomes in adults with moderate-to-severe psoriasis in the United States: a population study using electronic health records to examine patient-perceived treatment effectiveness, medication use, and healthcare resource utilization. <b>2018</b> , 18, 4	14
337	Psoriasis in Israel: demographic, epidemiology, and healthcare services utilization. <b>2018</b> , 57, 1068-1074	12
336	Validating a Selective S1P Receptor Modulator Syl930 for Psoriasis Treatment. <b>2018</b> , 41, 592-596	11
335	Gender Differences in Psoriasis. <b>2018</b> , 63-81	1
334	IL-23 Inhibitors for Psoriasis. <b>2018</b> , 7, 119-124	3
333	Association Between Psoriasis and Erectile Dysfunction: A Meta-Analysis. <b>2018</b> , 15, 839-847	6
332	Pharmacokinetics of tazarotene and acitretin in psoriasis. <b>2018</b> , 14, 919-927	18
331	Stigmatization in Psoriasis. <b>2018</b> , 3, 100-106	4
330	Psoriasis: Psychosomatic, somatopsychic, or both?. <b>2018</b> , 36, 698-703	10
329	Human-computer symbiosis: enhancing dermatologic care while preserving the art of healing. <b>2018</b> , 57, 1015-1016	1
328	Comparison of mental health outcomes among adults with psoriasis on biologic versus oral therapies: a population-based study. <b>2019</b> , 30, 135-140	7
327	Minimal clinically important difference (MCID) for work productivity and activity impairment (WPAI) questionnaire in psoriasis patients. <b>2019</b> , 33, 318-324	6
326	A cross-sectional study in young adults with psoriasis: potential determining factors in quality of life, life course and work productivity. <b>2019</b> , 30, 208-215	11
325	How Does Anxiety Affect Adults with Skin Disease? Examining the Indirect Effect of Anxiety Symptoms on Impairment Through Anxiety Sensitivity. <b>2019</b> , 43, 14-23	2
324	Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. <b>2019</b> , 394, 831-839	141

323	Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response. <b>2019</b> , 14, e0220868		81
322	Urinary orosomucoid: a new marker of cardiovascular risk in psoriatic patients?. <b>2019</b> , 15, 831-837		4
321	Pityriasis rubra pilaris: A study evaluating patient quality of life in 2 populations. <i>Journal of the American Academy of Dermatology</i> , <b>2019</b> , 81, 638-640	4-5	6
320	Quality of life, anxiety and depressive symptoms in patients with psoriasis: A case-control study. <b>2019</b> , 124, 109780		19
319	Total glucosides of paeony attenuates animal psoriasis induced inflammatory response through inhibiting STAT1 and STAT3 phosphorylation. <b>2019</b> , 243, 112121		18
318	Evaluating guselkumab: an anti-IL-23 antibody for the treatment of plaque psoriasis. <b>2019</b> , 13, 1993-2000		6
317	Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study. <b>2019</b> , 139, 2437-2446.e1		42
316	Anti IL-17 in psoriasis. <b>2019</b> , 15, 1185-1194		26
315	Use of the SF-12 questionnaire to assess physical and mental health status in patients with psoriasis. <b>2019</b> , 46, 1153-1159		3
314	Effects of Online Care on Functional and Psychological Outcomes in Patients with Psoriasis: A Randomized Controlled Trial. <i>Journal of the American Academy of Dermatology</i> , <b>2019</b> ,	4-5	7
313	Nitidine chloride induces S phase cell cycle arrest and mitochondria-dependent apoptosis in HaCaT cells and ameliorates skin lesions in psoriasis-like mouse models. <b>2019</b> , 863, 172680		5
312	Psoriasis. <b>2019</b> , 131-144		
311	PsA-Disk, a novel visual instrument to evaluate psoriatic arthritis in psoriatic patients: an Italian derma-rheuma multicentre study. <b>2019</b> , 10, 2040622319847056		3
310	State of the art and pharmacological pipeline of biologics for chronic plaque psoriasis. <b>2019</b> , 46, 90-99		24
309	Rationale, objectives and design of PURE, a prospective registry of patients with moderate to severe chronic plaque psoriasis in Canada and Latin America. <b>2019</b> , 19, 9		2
308	Betulinic acid suppresses Th17 response and ameliorates psoriasis-like murine skin inflammation. <b>2019</b> , 73, 343-352		12
307	Comparison of physical and mental functioning among moderate-to-severe psoriasis patients on biologic versus oral therapy. <b>2019</b> , 311, 453-460		2
306	The association between the socioeconomic status and anxiety-depression comorbidity in patients with psoriasis: a nationwide population-based study. <b>2019</b> , 33, 1555-1561		13

305	Narrowband ultraviolet B phototherapy improves quality of life of psoriasis and atopic dermatitis patients up to 3 months: Results from an observational multicenter study. <b>2019</b> , 35, 332-338		11
304	Efficacy and safety of tofacitinib for the treatment of chronic plaque psoriasis: a systematic review and meta-analysis. <b>2019</b> , 47, 2342-2350		10
303	Racial Differences in Perceptions of Psoriasis Therapies: Implications for Racial Disparities in Psoriasis Treatment. <b>2019</b> , 139, 1672-1679.e1		11
302	Extraarticular Manifestations: Uveitis, Colitis, Psoriasis. <b>2019</b> , 157-182		1
301	Optimal Biologic Selection for Treatment of Psoriatic Arthritis: the Approach to Precision Medicine. <b>2019</b> , 21, 21		3
300	Psoriasis Pathogenesis and Treatment. <b>2019</b> , 20,		427
299	Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities?. <b>2019</b> , 10, 279		57
298	Willingness to pay and quality of life in patients with pruritic skin disorders. <b>2019</b> , 311, 221-230		3
297	Treating to Target(s) With Interleukin-17 Inhibitors. <b>2019</b> , 23, 3S-34S		3
296	Construct validity and responsiveness of the Colombian version of Skindex-29. <i>British Journal of Dermatology</i> , <b>2019</b> , 181, 770-777	4	4
295	Protocol for a case-control diagnostic accuracy study to develop diagnostic criteria for psoriasis in children (DIPSOC study): a multicentre study recruiting in UK paediatric dermatology clinics. <b>2019</b> , 9, e028689		1
294	Cohort profile: the clinical 'Psoriasis in Adolescents' (PIA) cohort in Denmark. <b>2019</b> , 9, e031448		5
293	Analyzing the value of an educational program for psoriasis patients: a prospective controlled pilot study. <b>2019</b> , 19, 1535		3
292	How frequently does palmoplantar psoriasis affect the palms and/or soles? A systematic review and meta-analysis. <b>2019</b> , 36, 595-603		2
291	Pruritus and skin pain in psoriatic patients: the neglected symptoms. <b>2019</b> , 29, 429-430		
290	Mesenchymal Stem Cells Alleviate Moderate-to-Severe Psoriasis by Reducing the Production of Type I Interferon (IFN-I) by Plasmacytoid Dendritic Cells (pDCs). <b>2019</b> , 2019, 6961052		14
289	[Severity scores for childhood psoriasis: A systematic literature review]. <b>2019</b> , 146, 771-782		4
288	Risk of first-time and recurrent depression in patients with psoriasis: a population-based cohort study. <i>British Journal of Dermatology</i> , <b>2019</b> , 180, 116-121	4	20

287	Psychological Distress, Alexithymia and Alcohol Misuse in Patients with Psoriasis: A Cross-Sectional Study. <b>2019</b> , 26, 200-219		8
286	Ixekizumab for the treatment of psoriasis: an update on new data since first approval. <b>2019</b> , 15, 111-121		15
285	The devil is in the data: differences in drug persistence between SNIIRAM, the French national health insurance database, and psoriasis biologics intervention registers. <i>British Journal of Dermatology</i> , <b>2019</b> , 180, 8-10	4	2
284	Practical Guidelines for Managing Patients With Psoriasis on Biologics: An Update. <b>2019</b> , 23, 35-125		13
283	Effects of psychosocial interventions on patient-reported outcomes in patients with psoriasis: a systematic review and meta-analysis. <i>British Journal of Dermatology</i> , <b>2019</b> , 181, 939-945	4	11
282	Evaluating the cost-effectiveness of secukinumab in moderate-to-severe psoriasis: a Japanese perspective. <b>2018</b> , 1-9		1
281	Psoriasis-associated cutaneous pain: etiology, assessment, impact, and management. <b>2019</b> , 30, 435-440		12
280	Review of safety and efficacy of approved systemic psoriasis therapies. <b>2019</b> , 58, 649-658		47
279	Dose increase beyond labelled dose of biologics is associated with incremental pharmacy costs: results from a real-world study in the UK. <b>2019</b> , 30, 376-382		1
278	Hidradenitis suppurativa has an enormous impact on patients' lives. <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 82, 236-238	4.5	4
277	Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis. <b>2020</b> , 29, 369-380		0
276	Long-term safety and efficacy of secukinumab in patients with psoriasis and major psychiatric disorders: a case series. <b>2020</b> , 132, 172-175		3
275	Certolizumab pegol for the treatment of psoriatic arthritis and plaque psoriasis. <b>2020</b> , 16, 119-128		4
274	Our ambition in a changing landscape of psoriasis treatments. <b>2020</b> , 31, 105-107		
273	Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. <b>2020</b> , 1, CD011535		46
272	Psoriasis causes as much disability as other major medical diseases. <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 82, 256-257	4.5	5
271	Skin-related quality of life in children and adolescents with congenital melanocytic naevi - an analysis of self- and parent reports. <b>2020</b> , 34, 1105-1111		6
270	A novel S1P1 modulator IMM002 ameliorates psoriasis in multiple animal models. <b>2020</b> , 10, 276-288		7

269	Tildrakizumab: An Evidence-Based Review of Its Use in the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis. <b>2020</b> , 16, 903-916	4
268	Effects of disease severity on quality of life in patients with psoriasis. <b>2020</b> , 33, e14422	1
267	Assessing the Effect of Demographic Background on Barriers to Seek Medical Attention for Psoriasis. <b>2020</b> , 5, 174-177	
266	Adjunctive Use of Calcipotriene/Betamethasone Dipropionate Foam in a Real-World Setting Curtails the Cost of Biologics Without Reducing Efficacy in Psoriasis. <b>2020</b> , 10, 1383-1396	1
265	Reliability and validity of the Chinese version of the Patient Health Questionnaire-9 (C-PHQ-9) in patients with psoriasis: a cross-sectional study. <b>2020</b> , 10, e033211	4
264	Zwei Fragen könnten reichen für Erkennung von Depressionen bei Patienten mit Psoriasis: eine multizentrische Studie. <b>2020</b> , 18, 1115-1127	
263	Disease burden and treatment needs of patients with psoriasis in sexually-sensitive and visible body areas: results from a large-scale survey in routine care. <b>2020</b> , 30, 267-278	2
262	An Analysis of the Perception of Psoriasis Symptoms and the Impact on Willingness to Seek Medical Attention. <b>2020</b> , 5, 109-113	
261	Metagenomic analysis of gut microbiota in non-treated plaque psoriasis patients stratified by disease severity: development of a new Psoriasis-Microbiome Index. <b>2020</b> , 10, 12754	21
260	Anticipated and Perceived Stigma Among Patients With Psoriasis. <b>2020</b> , 5, 93-99	1
259	Depressive symptoms and insecure attachment predict disability and quality of life in psoriasis independently from disease severity. <b>2021</b> , 313, 431-437	1
258	Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL). <b>2020</b> , 10, 1099-1109	4
257	Impact of oral lesions on the quality of life of psoriatic individuals: A case-control study. <b>2021</b> , 27, 1813-1821	0
256	Nutritional treatment for psoriasis: A case report. <b>2020</b> , 8, 240-240	
255	Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials. <b>2020</b> , 156, 1344-1353	5
254	Investigation of predictors of interest in a brief mindfulness-based intervention and its effects in patients with psoriasis at a rehabilitation clinic (SkinMind): an observational study and randomised controlled trial. <b>2020</b> , 10, e033952	1
253	Relationships between the acceptance of illness, quality of life and satisfaction with life in psoriasis. <b>2020</b> , 37, 948-955	3
252	Two questions may be enough - screening for depression in patients with psoriasis: a multicenter study. <b>2020</b> , 18, 1115-1125	1



251	The role of Th17 cells in psoriasis. <b>2020</b> , 68, 296-309	17
250	Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study. <b>2020</b> , 21, 881-890	12
249	Metagenomics: Techniques, Applications, Challenges and Opportunities. <b>2020</b> ,	2
248	Development and Content Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM) for Assessment of Plaque Psoriasis. <b>2020</b> , 10, 1255-1272	4
247	Pain associated with psoriasis: systematic scoping review protocol. <b>2020</b> , 10, e031461	2
246	Long-term safety and efficacy of adalimumab in psoriasis: a multicentric study focused on infections (connecting study). <b>2020</b> , 37, 428-434	3
245	Nonadherence to Treatment and Patient-Reported Outcomes of Psoriasis During the COVID-19 Epidemic: A Web-Based Survey. <b>2020</b> , 14, 1403-1409	12
244	Disease burden and quality of life in patients with moderate-to-severe psoriasis stratified according to previous systemic treatment exposure. <b>2020</b> , 34, 2454-2455	1
243	[Psoriasis]. <b>2020</b> , 162, 43-50	
242	Topical Therapies for Psoriasis in Phase 3 Trials. <b>2020</b> , 9, 331-338	
241	Treatment Goals in Psoriasis: Which Outcomes Matter Most?. <b>2020</b> , 21, 505-511	7
240	Indoor salt water baths followed by artificial ultraviolet B light for chronic plaque psoriasis. <b>2020</b> , 5, CD011941	1
239	Physical activity engagement and responses to exercise in plaque psoriasis: a multifactorial investigation of influential factors. <b>2020</b> , 1-7	2
238	Long-Term Single Center Experience in Treating Plaque Psoriasis With Guselkumab. <b>2020</b> , 24, 588-595	13
237	Psychosocial burden and body mass index are associated with dermatology-related quality of life in psoriasis patients. <b>2020</b> , 30, 140-147	3
236	Impact of patient psoriasis on partner quality of life, sexuality and empathy feelings: a study in 183 couples. <b>2020</b> , 34, 2044-2050	1
235	An economic evaluation of risankizumab versus other biologic treatments of moderate to severe plaque psoriasis in Japan. <b>2020</b> , 1-11	3
234	Comparative study of the efficacy and safety of secukinumab vs ixekizumab in moderate-to-severe psoriasis after 1 year of treatment: Real-world practice. <b>2020</b> , 33, e13313	10

233	Acceptance of Illness, Satisfaction with Life, Sense of Stigmatization, and Quality of Life among People with Psoriasis: A Cross-Sectional Study. <b>2020</b> , 10, 413-430	18
232	[Management of Psoriasis by Family Physicians: Referral Algorithm and Shared Management with Dermatology]. <b>2020</b> ,	
231	Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis. <b>2020</b> , 99, 53-61	11
230	Efficacy and safety of guselkumab for the treatment of patients with moderate-to-severe plaque psoriasis: A metaanalysis of randomized clinical trials. <b>2020</b> , 19, 433-440	
229	Characterization of insufficient responders to ustekinumab in patients with moderate-to-severe psoriasis in the US Corrona Psoriasis Registry. <b>2021</b> , 32, 907-915	1
228	Treatment of psoriatic skin lesions with a new Er:Yag laser technology: A case series study. <b>2020</b> , 33, e13264	1
227	Correct performance of subcutaneous injections in plaque psoriasis: comparison of trained and untrained patients with different application systems in routine clinical care. <b>2021</b> , 32, 898-906	
226	How is safety of dermatology drugs assessed: trials, registries, and spontaneous reporting. <b>2020</b> , 19, 449-457	3
225	Pathogen-Associated Molecular Pattern-Induced TLR2 and TLR4 Activation Increases Keratinocyte Production of Inflammatory Mediators and is Inhibited by Phosphatidylglycerol. <b>2020</b> , 97, 324-335	11
224	Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies. <b>2020</b> , 34, 2830-2838	20
223	Effects of anxiety on preferences for generic medicines in Australia. <b>2021</b> , 36, 187-195	
222	An update on the impact of depression on the treatment of psoriasis. <b>2021</b> , 22, 695-703	1
221	Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized Phase III VOLTAIRE-PSO study. <b>2021</b> , 21, 87-96	2
220	Validation of the Skindex-17 quality of life assessment instrument for a Brazilian population. <b>2021</b> , 96, 51-58	1
219	Periodontitis and the impact of oral health on the quality of life of psoriatic individuals: a case-control study. <b>2021</b> , 25, 2827-2836	1
218	The characteristics and impact of pruritus in adult dermatology patients: A prospective, cross-sectional study. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> , 84, 691-700	4.5 8
217	Brodalumab for the treatment of moderate-to-severe plaque-type psoriasis: a real-life, retrospective 24-week experience. <b>2021</b> , 35, 693-700	7
216	Characterization of insufficient responders to anti-tumor necrosis factor therapies in patients with moderate to severe psoriasis: real-world data from the US Corrona Psoriasis Registry. <b>2021</b> , 32, 302-309	7

215	Psoriasis Associated With Tumor Necrosis Factor Inhibitors in Children With Inflammatory Diseases. <b>2021</b> , 73, 215-220		6
214	Vermittlung des biopsychosozialen Modells in der universitären Lehre: Konzeption und Durchführung eines Seminars mit Betroffenen und Experten aus Dermatologie und Psychosomatik. <b>2021</b> , 47, 162-168		
213	Psoriasis. <b>2021</b> , 89-103		1
212	Biologic therapies for plaque type psoriasis in patients with previous malignant cancer: long-term safety in a single- center real-life population. <b>2021</b> , 1-5		4
211	Impact of an eHealth Smartphone App on the Mental Health of Patients With Psoriasis: Prospective Randomized Controlled Intervention Study. <b>2021</b> , 9, e28149		1
210	Efficacy of Systemic Treatments of Nail Psoriasis: A Systemic Literature Review and Meta-Analysis. <b>2021</b> , 8, 620562		4
209	Off-Label Treatments for Pediatric Psoriasis: Lessons for the Clinic. <i>Psoriasis: Targets and Therapy</i> , <b>2021</b> , 11, 1-20	2.4	3
208	The Keloid Intervention Benefit Inventory 21: A New Assessment Tool for the Quality of Life of Patients with Auricular Keloids. <b>2021</b> , 37, 370-375		
207	eHealth Smartphone Application for Psoriasis Patients Improves Mental Health, If Not Used Too Frequently: A Prospective Randomized Controlled Intervention Study. (Preprint).		
206	Dysregulated Dermal Mesenchymal Stem Cell Proliferation and Differentiation Interfered by Glucose Metabolism in Psoriasis. <b>2021</b> , 14, 85-93		2
205	Validation of psoriasis disability index (PDI) questionnaire Sinhala version. <b>2021</b> , 1		
204	A phase 2b, randomized clinical trial of tapinarof cream for the treatment of plaque psoriasis: Secondary efficacy and patient-reported outcomes. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> , 84, 624-631	4.5	13
203	The Experience of Blogging about Visible and Long-term Skin Conditions: an Interpretative Phenomenological Analysis (Preprint).		
202	Biologics recommendations for patients with psoriasis: a critical appraisal of clinical practice guidelines for psoriasis. <b>2021</b> , 1-36		1
201	Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. <b>2021</b> , 4, CD011535		11
200	Pain Management in Painful Psoriasis and Psoriatic Arthropathy: Challenging and Intricately Intertwined Issues Involving Several Systems. <b>2021</b> , 25, 36		0
199	Management of a Chronic Skin Disease in Primary Care: An Analysis of Early-Career General Practitioners' Consultations Involving Psoriasis. <b>2021</b> , 11, e2021055		
198	Guidelines for Management of Psoriasis. <b>2021</b> , 13, 168-174		1

197	Psoriatic arthritis. <b>2021</b> , 48, 741-749	3
196	Prevalence and Characteristics of Psoriasis in Romania-First Study in Overall Population. <b>2021</b> , 11,	1
195	Clinical and trichoscopic features in various forms of scalp psoriasis. <b>2021</b> , 35, 1830-1837	3
194	Key Signaling Pathways in Psoriasis: Recent Insights from Antipsoriatic Therapeutics. <i>Psoriasis: Targets and Therapy</i> , <b>2021</b> , 11, 83-97	2.4 3
193	Quality of life in children with psoriasis: results from a monocentric study. <b>2021</b> , 156,	0
192	Saponin Momordin Ic Modulates HaCaT Cell Proliferation and Apoptosis via the Wnt/-Catenin Pathway. <b>2021</b> , 2021, 5522164	0
191	Identifying Relevant Disease Characteristics Regarding Psoriasis in Germany: A Retrospective Web Search Data Analysis (Preprint).	0
190	Community pharmacists' perceptions and role in the management of common dermatological problems in Lebanon: a cross-sectional study. <b>2021</b> , 29, 573-579	1
189	Glycerol Improves Skin Lesion Development in the Imiquimod Mouse Model of Psoriasis: Experimental Confirmation of Anecdotal Reports from Patients with Psoriasis. <b>2021</b> , 22,	3
188	New topical therapies for psoriasis. <b>2021</b> , 2, 262	1
187	Risk of psychiatric diseases among patients with psoriasis in Korea: A 12-year nationwide population-based cohort study. <b>2021</b> , 48, 1763-1771	0
186	MANAGEMENT OF PSORIASIS: A COMPARATIVE CLINICAL STUDY OF STANDARD AYURVEDA & ALLOPATHIC PROTOCOLS. <b>2021</b> , 9, 290-301	
185	Skin-Disease Specific and Generic Psychometric Measures in Patients with Psoriasis. <b>2021</b> , 11, 1999-2015	0
184	Functional Magnetic Resonance Imaging and Applications in Dermatology.. <b>2021</b> , 1, 100015	
183	A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study. <b>2021</b> , 21, 924	3
182	Does Psoriasis influence female sexual dysfunction? A multicentric Italian case-control study. <b>2021</b> ,	0
181	Role of Janus Kinase Inhibitors in Therapy of Psoriasis. <b>2021</b> , 10,	3
180	Portraying molecular modulation and therapeutic aspects of psoriasis: Retrospection and current status. <b>2021</b> , 1243, 130770	

179	Burden of Disease for Psoriasis in Argentina, Brazil, Colombia, and Mexico. <b>2021</b> , 26, 126-134	
178	Deciphering the mechanism of Fang-Ji-Di-Huang-Decoction in ameliorating psoriasis-like skin inflammation via the inhibition of IL-23/Th17 cell axis. <b>2021</b> , 281, 114571	4
177	The Skin. <b>2021</b> ,	
176	Effects of Patients' Expectation in Dermatology: Evidence from Experimental and Clinical Placebo Studies and Implications for Dermatologic Practice and Research. <b>2021</b> , 237, 857-871	
175	Depressive, anxiety, stress, and insomnia symptoms in patients with psoriasis: a cross-sectional study. <b>2021</b> , 38, 510-519	0
174	Biologics for chronic plaque psoriasis.	2
173	Ustekinumab for plaque psoriasis.	2
172	Psoriasis: Overview and Diagnosis. <b>2018</b> , 1-16	7
171	Quality of Life in Autoimmune Blistering Diseases. <b>2015</b> , 623-631	2
170	Quality of life issues in psoriasis. <b>2008</b> , 165-177	1
169	Construct Validity of the Questionnaire on Experience with Skin Complaints (Short Form). <b>2007</b> , 23, 176-184	2
168	Psychological burden of psoriatic patients in a German university hospital dermatology department. <b>2021</b> , 48, 794-806	3
167	Development of the US PSORIQoL: a psoriasis-specific measure of quality of life. <b>2006</b> , 060720080827131	1
166	The meaning of youth physical activity experiences among individuals with psoriasis: A retrospective inquiry. <b>2019</b> , 25, 374-388	1
165	Evolution of Cooperation Patterns in Psoriasis Research: Co-Authorship Network Analysis of Papers in Medline (1942-2013). <b>2015</b> , 10, e0144837	19
164	Psoriasis: correlation between severity index (PASI) and quality of life index (DLQI) in patients assessed before and after systemic treatment. <b>2013</b> , 88, 760-3	19
163	Quality of life of patients with psoriasis. <b>2020</b> , 28, 219-225	1
162	Possible Role of Phosphatidylglycerol-Activated Protein Kinase C- $\beta$ in Keratinocyte Differentiation. <b>2017</b> , 11, 59-71	3

161	The Psoriasis Pathogenesis and the Metabolic Risk. <b>2018</b> , 12, 70-79	1
160	Balneotherapy in Psoriasis Rehabilitation. <b>2017</b> , 31, 1163-1168	6
159	Etanercept: a soluble TNF- $\alpha$ receptor in the treatment of psoriasis. <b>2007</b> , 4, 665-672	1
158	Psoriasis: clinical and epidemiological features and therapy issues. <b>2018</b> , 94, 67-76	6
157	Implications of self-esteem in the quality of life in patients with psoriasis. <b>2020</b> , 20, 202	6
156	Management of pediatric psoriasis. <b>2012</b> , 41, e1-7	22
155	Psychiatric evaluation in dermatology: an overview. <b>2013</b> , 58, 39-43	23
154	The Pattern of Psoriatic Arthritis in Kashmir: A 6-Year Prospective Study. <b>2015</b> , 7, 356-61	2
153	Efficacy of adding topical simvastatin to topical calcipotriol on improvement of cutaneous plaque psoriasis. <b>2014</b> , 3, 11	2
152	Patients with psoriasis have a higher risk of schizophrenia: A systematic review and meta-analysis of observational studies. <b>2019</b> , 65, 141-145	6
151	Relationship between Helicobacter pylori infection and psoriasis. <b>2014</b> , 34, 241-4	7
150	Double trouble: psoriasis and cardiometabolic disorders. <b>2018</b> , 29, 189-194	3
149	Guselkumab for the treatment of psoriasis - evidence to date. <b>2019</b> , 8, 212594	21
148	Quality of Life and Psychopathology in Lichen Planus: a Neglected Disease Burden. <b>2021</b> ,	2
147	Risk of infections in psoriasis: assessment and challenges in daily management. <b>2021</b> , 17, 1211-1220	1
146	Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study-the BeNeBio study. <b>2021</b> , 22, 707	1
145	Psoriasis Vulgaris and Arthropathica. <b>2001</b> , 267-282	
144	Die Psoriasispathogenese aus heutiger Sicht. <b>2001</b> , 475-478	

- 143 The Impact of Calcipotriol-based Topical Combination Therapy on Health-related Quality of Life in the Patients with Psoriasis Vulgaris. **2005**, 67, 397-403 1
- 142 Cyclosporin-MEPC for Treatment of Psoriasis: Questionnaire Survey on Members of Western Division of Japanese Dermatological Association. **2005**, 67, 252-257 1
- 141 Impact of psoriasis on quality of life in Kuwait. **2006**, 060720080827202
- 140 The psychological impact of skin disease. **2007**, 2007,
- 139 SECTION XII: Skin and Hair. **2007**, 677-678
- 138 Skin disease caused by changes in the immune system and infection. **2007**, 695-708
- 137 33 Psychodermatologie. **2009**, 317-321
- 136 Application of 3 mg/kg of Cyclosporine A (NEORAL) Once Daily is Effective for Severe and Moderate Psoriasis. **2009**, 71, 63-69
- 135 Adalimumab for the treatment of psoriasis. **2009**, 4, 15-21 1
- 134 Management of psoriasis. **2009**, 102, 631-6
- 133 Psoriasis. **2010**, 193-205
- 132 Usefulness of Sequential Topical Therapy with Calcipotriol Ointment and Betamethasone Butyrate Propionate Ointment in Patients with Psoriasis Vulgaris. **2010**, 72, 163-168
- 131 Prevention of Psoriasis. **2011**, 151-160
- 130 General Aspects of Treatment. 1-34
- 129 The burden of psoriasis and treatment options. **2010**, 2010,
- 128 Neueste Erkenntnisse und Blick in die Zukunft. **2011**, 1-48
- 127 Biologics for chronic plaque psoriasis.
- 126 Psoriasis Vulgaris and Arthropathica. **2011**, 325-348

- 125 Prevention of Psoriasis. **2011**, 89-98
- 124 Dermatologische Problemzonen. **2011**, 103-121
- 123 Treatment options in psoriasis. **2011**, 2011,
- 122 National Psoriasis Foundation: evolving role in psoriasis treatment. **2011**, 122-133
- 121 JUSTIFICACI3N DE LA IMPORTANCIA DE VALORAR EL RIESGO CARDIOVASCULAR EN PSORIASIS. **2012**, 1-27
- 120 The diagnosis and management of psoriasis. **2013**, 2013,
- 119 Ustekinumab for plaque psoriasis.
- 118 Psoriasis and Comorbidities. **2014**, 277-299
- 117 Use of Lasers for the Treatment of Psoriasis and Vitiligo. **2014**, 223-247
- 116 33 Psychodermatologie. **2014**, 272-274
- 115 The Immunomodulatory/Immunosuppressive Classification System. **2014**, 361-372
- 114 Assessment of Health-Related Quality of Life in Patients with Psoriasis in Comparison with Normal Subjects in Shiraz Iran. **2014**, 15,
- 113 Psoriasis and Aging. **2015**, 1-7
- 112 Psychological and Social Implications of Aging Skin: Normal Aging and the Effects of Cutaneous Disease. **2015**, 1-14
- 111 Introduction. **2016**, 1-5
- 110 Psychological and Social Implications of Aging Skin: Normal Aging and the Effects of Cutaneous Disease. **2017**, 1645-1656
- 109 Psoriasis and Aging. **2017**, 1065-1070
- 108 Psychodermatologie. **2017**, 317-321



- 107 Quality of Life in Psoriasis Patients and Its Correlation with Disease Severity. **2018**, 26, 1-5
- 106 Psorãse Ñvisã do dermatologista. **2018**, 6-12
- 105 Depigmentory Effects of Keishibukuryogankayokuinin in Human Epidermal Melanocytes. **2019**, 11, 869-879
- 104 Evaluation of Social Anxiety Levels and Related Factors in Psoriasis Patients: A Controlled, Cross-Sectional Study. **2020**, 57, 148-153
- 103 Hard life of a patient with psoriasis - treatment from psychodermatological point of view. **2019**, 13, 92-95
- 102 Influence of focal infection on the immune status of psoriasis patients. **2019**, 95, 16-24 1
- 101 The relationship between alexithymia, anxiety, depression, and severity of the disease in psoriasis patients. 1
- 100 Assessment of the benefit of achieving complete versus almost complete skin clearance in psoriasis: a patient's perspective. **2020**, 1-7 1
- 99 Psoriasis y salud mental. **2020**, 35, 417-419
- 98 The Skin. **2022**,
- 97 Psoriasis: A Comprehensive Review on the Aetiopathogenesis and Recent Advances in Long-Term Management of Patients with Plaque Psoriasis. **2020**, 11, 373-401
- 96 The Skin Metagenomes: Insights into Involvement of Microbes in Diseases. **2020**, 189-198
- 95 The Difficulty of German Information Booklets on Psoriasis and Psoriatic Arthritis: Automated Readability and Vocabulary Analysis. **2020**, 3, e16095 2
- 94 Multidisciplinary approach to psoriasis in the Spanish National Health System: A social return on investment study. **2020**, 7, 50-56 2
- 93 Psoriasis Vulgaris and Arthropathica. **2005**, 291-308
- 92 Psoriasis. **2005**, 109-117
- 91 Psychosomatische Dermatologie. **2005**, 35-46
- 90 Biological treatments for psoriasis. **2006**, 3, 425-436

89	Mindfulness-based cognitive therapy as a clinical intervention with psoriasis patients through the lens of the clinically modified Buddhist psychological model: a qualitative study. <b>2020</b> , 23, 806-825	1
88	Psoriasis and Comorbidities. <b>2021</b> , 363-397	
87	Psychosocial effect of common skin diseases. <b>2002</b> , 48, 712-6	62
86	What is beauty?: Royal Victoria Hospital, Wednesday 1st October 2008. <b>2009</b> , 78, 84-9	1
85	Efalizumab in the treatment of psoriasis. <b>2007</b> , 1, 301-9	11
84	A practical approach to monitoring patients on biological agents for the treatment of psoriasis. <b>2010</b> , 3, 20-6	5
83	The rationale behind topical vitamin d analogs in the treatment of psoriasis: where does topical calcitriol fit in?. <b>2010</b> , 3, 46-53	9
82	Etanercept in psoriasis: the evidence of its therapeutic impact. <b>2007</b> , 2, 51-62	2
81	Impact of Baseline Disease Severity Over 26 and 52 Weeks of Treatment with Calcitriol Ointment 3µg/g in Patients with Mild-to-moderate Plaque Psoriasis. <b>2012</b> , 5, 28-33	1
80	Psoriasis: The Poster Child for Bench-to-bedside Translational Medicine. <b>2015</b> , 8, 14-6	
79	The Relationship between Disease, Work and Sickness Absence among Psoriasis Patients. <b>2015</b> , 44, 1506-13	5
78	More Biologic Therapies Expected To Treat Advanced Plaque Psoriasis. <b>2016</b> , 41, 388-90	2
77	The Challenge of Managing Psoriasis: Unmet Medical Needs and Stakeholder Perspectives. <b>2016</b> , 9, 504-513	49
76	Effects of Topical Application of Betamethasone on Imiquimod-induced Psoriasis-like Skin Inflammation in Mice. <b>2016</b> , 62, E79-E88	7
75	Cost-Effectiveness Analysis of Ixekizumab vs Etanercept and Their Manufacturer-Recommended Dosing Regimens in Moderate to Severe Plaque Psoriasis. <b>2017</b> , 16, 964-970	1
74	Psoriasis and the Digital Landscape: YouTube as an Information Source for Patients and Medical Professionals. <b>2018</b> , 11, 36-38	3
73	Effect of Adalimumab on Gene Expression Profiles of Psoriatic Skin and Blood. <b>2016</b> , 15, 988-94	6
72	The Challenge of Variable Costs in Decisions Based on Cost-Effectiveness Evidence: A Case Study for Brodalumab. <b>2019</b> , 12, 22-26	

71	Erbium-doped Yttrium Aluminium Garnet (Er:YAG) Laser Resurfacing Restores Normal Function and Cosmesis in Patients with Severe Rhinophyma. <b>2019</b> , 12, 28-33		2
70	New and Emerging Topical Therapies for Psoriasis and Atopic Dermatitis. <b>2019</b> , 12, 28-34		31
69	Pattern of pediatric skin disorders in Murtala Muhammad Specialist Hospital Kano, Nigeria. <b>2020</b> , 91, e2020184		
68	Assessment of the Toronto Psoriatic Arthritis Screen 2 as a Screening Tool for Psoriasis. <b>2021</b> , 12034754211061085		
67	Progressive Symmetrical Erythrokeratoderma-Like Psoriasis: A New Case Report. <b>2021</b> , 11, 293-303		
66	THE EXPERIENCE OF BLOGGING ABOUT VISIBLE AND LONG-TERM SKIN CONDITIONS: AN INTERPRETATIVE PHENOMENOLOGICAL ANALYSIS (Preprint).		
65	A Multi-Center, Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study Evaluating Efficacy and Safety of Vunakizumab in Patients with Moderate-to-Severe Plaque Psoriasis.. <i>Journal of the American Academy of Dermatology</i> , <b>2022</b> ,	4.5	1
64	Evaluation of factors associated with sexual dysfunction in psoriasis in a cohort of 1409 patients.. <b>2021</b> ,		0
63	Immune mechanisms of psoriasis. New strategies of biotherapy. <b>2010</b> , 86, 35-47		11
62	Proteome technologies in studying the pathogenesis of psoriasis. <b>2011</b> , 87, 27-33		1
61	Loss of Indoleamine-2,3-Dioxygenase-1 (IDO1) in Knockout Mice Does Not Affect the Development of Skin Lesions in the Imiquimod-Induced Mouse Model of Psoriasis.. <b>2022</b> , 15, 11786469221078191		
60	Introduction to Biologic Therapy for Psoriasis. <b>2022</b> , 1-8		
59	Identifying and managing psoriasis-associated comorbidities: the IMPACT research programme. <b>2022</b> , 10, 1-240		
58	Health-related quality of life differs by race/ethnicity in North American patients with psoriasis: results from PSOLAR.. <b>2022</b> ,		
57	The interleukin 1 receptor antagonist anakinra to reduce disease severity of palmoplantar pustulosis in adults: APRICOT RCT and PLUM mechanistic study. <b>2022</b> , 9, 1-106		
56	Can Biological Drugs Diminish the Risk of Sarcopenia in Psoriatic Patients? A Systematic Review.. <b>2022</b> , 12,		
55	Nail psoriasis: dynamics of the clinical course during anti-IL-17 therapy. <b>2022</b> , 38-45		0
54	Current advances in biological therapy of psoriasis: efficacy of guselkumab in real clinical practice. <b>2022</b> , 71-78		

53	IL-17A in the treatment of nail psoriasis. <b>2021</b> , 24, 347-354		
52	Assessment of Life Quality, Stress and Physical Activity Among Patients with Psoriasis.. <b>2021</b> , 12, 395		3
51	Clinical validation of digital biomarkers and machine learning models for remote measurement of psoriasis and psoriatic arthritis.		0
50	Incidence Rates of Psoriasis in Children with Inflammatory Bowel Disease and Juvenile Arthritis Treated with TNFi Agents and DMARDs.. <b>2022</b> ,		0
49	Table_1.DOCX. <b>2019</b> ,		
48	Curcumin: A review of its efficacy in the management of psoriasis. <b>2022</b> , 12,		0
47	Comparison of the Efficacy and Safety of Biologics (Secukinumab, Ustekinumab, and Guselkumab) for the Treatment of Moderate-to-Severe Psoriasis: Real-World Data from a Single Korean Center. <b>2022</b> , 10, 1058		0
46	Clinical efficacy of the rotation of phototherapy methods (PUVA therapy and mid-wavelength ultraviolet therapy (311 nm)) in patients with moderate to severe forms of psoriasis. <b>2015</b> , 91, 67-75		
45	Efficacy, quality of life and treatment satisfaction: an indirect comparison of calcipotriol/betamethasone dipropionate cream versus foam for treatment of psoriasis.. <b>2022</b> , 1-24		1
44	Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. <b>2022</b> , 2022,		2
43	Transforming the treatment of psoriasis to the 21st century: Detecting subclinical therapeutic response to secukinumab using optical coherence tomography as a prognostic indicator.		
42	Anxiety, depression, and sexual dysfunction in patients with psoriasis. <i>Turk Dermatoloji Dergisi</i> , <b>2022</b> , 16, 62	0.4	0
41	Comorbidity in Adult Psoriasis: Considerations for the Clinician. <i>Psoriasis: Targets and Therapy</i> , Volume 12, 139-150	2.4	0
40	Incidence and prevalence of psoriasis in multi-ethnic Johor Bahru, Malaysia: a population-based cohort study using electronic health data routinely captured in Teleprimary Care ( TPC ) clinical information system from 2010 to 2020. <i>British Journal of Dermatology</i> ,	4	
39	Molecular mechanisms of Biyu decoction as treatment for psoriasis: A network pharmacology and molecular docking study. <i>World Journal of Clinical Cases</i> , <b>2022</b> , 10, 7224-7241	1.6	
38	Work productivity in real-life employed patients with plaque psoriasis: Results from the ProLOGUE study.		
37	Correlation of catecholamine content and clinical influencing factors in depression among psoriasis patients: a case-control study. <b>2022</b> , 16,		
36	How important is subjective well-being for patients? A qualitative interview study of people with psoriasis.		

- 35 Multivariable Predictive Models to Identify the Optimal Biologic Therapy for Treatment of Patients With Psoriasis at the Individual Level. 1
- 34 Tacrolimus nanocrystals microneedle patch for plaque psoriasis. **2022**, 627, 122207 0
- 33 A Retrospective Real-World Study of the Effectiveness and Tolerability of Tildrakizumab in UK Adults with Moderate-to-Severe Chronic Plaque Psoriasis. **2022**, 12, 2343-2354 0
- 32 Plasma Levels of Interleukins 36 and 37 in Patients with Psoriasis and Their Correlation with Disease Activity Parameters. **2022**, 11, 5254 0
- 31 Long-Term Results of a Multimodal Treatment Regimen in Patients With Auricular Keloids. 014556132211332 0
- 30 DLQI in Females: Important Disorders with Low DLQI. **2022**, 277-289 0
- 29 Innovation That Drives Your Dermatological Future. 36-43 0
- 28 PASI 90/100, DLQI 0/1, and IL-17 Receptor/Cytokine: Does it Make a Difference and Are We Ambitious Enough?. 36-44 0
- 27 Vitamin D May Be Connected with Health-Related Quality of Life in Psoriasis Patients Treated with Biologics. **2022**, 12, 1857 0
- 26 Deucravacitinib in moderate-to-severe psoriasis. 0
- 25 DNA methylation markers in peripheral blood for psoriatic arthritis. **2022**, 1
- 24 Investigating modifiable pathways in psoriasis: a Mendelian randomization study. **2022**, 0
- 23 The Skin. **2023**, 0
- 22 Clinical Overview of Psoriasis and Psoriatic Arthritis. **2022**, 345-365 0
- 21 Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway. 120347542211416 0
- 20 Factors Affecting Patient Satisfaction in Dermatology Clinics in Saudi Arabia. **2022**, 0
- 19 Female sexual dysfunction in psoriasis: a systematic review and meta-analysis using the Female Sexual Function Index. 0
- 18 Epidemiology of Psoriasis in Portugal: A Population-Based Study. 0

- 17 Antidepressants and the risk of psoriasis induction: A case-control study. **2023**, 12, 16
- 16 Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib. **2023**, 15, 1759720X2211499
- 15 Apremilast Use in Severe Psoriasis: Real-World Data from Central and Eastern Europe. **2023**, 40, 1787-1802
- 14 A patient's experience of recalcitrant psoriasis and psoriatic arthritis. **2023**, 48, 145-146
- 13 Quality of Life Evaluation in Psoriasis Patients Starting a Biological Treatment: The Importance of a More Comprehensive Assessment of Disease Burden. 87-91
- 12 Discovery of orally bioavailable inhibitors of MALT1 with in vivo activity for psoriasis. **2023**, 82, 129155
- 11 Long-Term Efficacy, Safety, and Drug Survival of Guselkumab in Patients with Psoriasis: Real-World Data from the Czech Republic BIOREP Registry. **2023**, 13, 787-801
- 10 Promising prospects of lipid-based topical nanocarriers for the treatment of psoriasis. **2023**, 10, 100123
- 9 Neutrophil extracellular trap: A key player in the pathogenesis of autoimmune diseases. **2023**, 116, 109843
- 8 Proyecto CUDERMA: Consenso Delphi de los indicadores de calidad para la certificaci3n de las unidades de dermatolog3a de atenci3n en psoriasis. **2023**,
- 7 Quantitative proteomic analysis of human serum using tandem mass tags to predict cardiovascular risks in patients with psoriasis. **2023**, 13,
- 6 Smoking is an independent but not a causal risk factor for moderate to severe psoriasis: A Mendelian randomization study of 105,912 individuals. 14,
- 5 Central Pain Sensitization in Patients with Chronic Plaque Psoriasis.
- 4 The Role of Adipokines in the Pathogenesis of Psoriasis. **2023**, 24, 6390
- 3 Real-world systemic treatment of patients with psoriasis: A retrospective study based on German claims data.
- 2 Speed of clinical improvement in the real-world setting from patient-reported Psoriasis Symptoms and Signs Diary: Secondary outcomes from the Psoriasis Study of Health Outcomes through 12 weeks.
- 1 Deucravacitinib, a selective tyrosine kinase 2 inhibitor, for the treatment of moderate-to-severe plaque psoriasis. 1-8